



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification⁶ : A01N 37/18, 37/34, A61K 31/16, 31/275</p>	A1	<p>(11) International Publication Number: WO 96/01558</p> <p>(43) International Publication Date: 25 January 1996 (25.01.96)</p>														
<p>(21) International Application Number: PCT/US95/08226</p> <p>(22) International Filing Date: 10 July 1995 (10.07.95)</p> <p>(30) Priority Data:</p> <table border="0"> <tr> <td>08/272,532</td> <td>11 July 1994 (11.07.94)</td> <td>US</td> </tr> <tr> <td>08/457,442</td> <td>1 June 1995 (01.06.95)</td> <td>US</td> </tr> </table> <p>(60) Parent Applications or Grants</p> <p>(63) Related by Continuation</p> <table border="0"> <tr> <td>US</td> <td>08/272,532 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>11 July 1994 (11.07.94)</td> </tr> <tr> <td>US</td> <td>08/457,442 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>1 June 1995 (01.06.95)</td> </tr> </table> <p>(71)(72) Applicants and Inventors: PATE, David, W. [US/NL]; Postbus 1397, NL-1000 BJ Amsterdam (NL). JARVINEN, Tomi [FI/FI]; Sompatie 3 C1, FIN-70200 Kuopio (FI). JARVINEN, Kristiina [FI/FI]; Sompatie 3 C1, FIN-70200 Kuopio (FI). URTTI, Arto [FI/US]; 8 Whittier Court, Mill Valley, CA 94941 (US).</p> <p>(74) Agents: KIT, Gordon et al.; Sughrue, Mion, Zinn, MacPeak & Seas, Suite 800, 2100 Pennsylvania Avenue, N.W., Washington, DC 20037-3202 (US).</p>		08/272,532	11 July 1994 (11.07.94)	US	08/457,442	1 June 1995 (01.06.95)	US	US	08/272,532 (CIP)	Filed on	11 July 1994 (11.07.94)	US	08/457,442 (CIP)	Filed on	1 June 1995 (01.06.95)	<p>(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).</p> <p>Published <i>With international search report.</i></p>
08/272,532	11 July 1994 (11.07.94)	US														
08/457,442	1 June 1995 (01.06.95)	US														
US	08/272,532 (CIP)															
Filed on	11 July 1994 (11.07.94)															
US	08/457,442 (CIP)															
Filed on	1 June 1995 (01.06.95)															
<p>(54) Title: ANANDAMIDE ANALOGUE COMPOSITIONS AND METHOD OF TREATING INTRAOCULAR HYPERTENSION USING SAME</p>																
<p>(57) Abstract</p> <p>Anandamide analogues useful for the treatment of intraocular hypertension, as well as ophthalmic compositions comprising the same and a cyclodextrin, and methods of use of these compounds to treat intraocular hypertension.</p>																

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

ANANDAMIDE ANALOGUE COMPOSITIONS AND METHOD OF TREATING
INTRAOCULAR HYPERTENSION USING SAME

FIELD OF THE INVENTION

5 The present invention relates to anandamide analogues useful for the treatment of intraocular hypertension, as well as ophthalmic compositions comprising the same and a cyclodextrin, and methods of use of said compositions to treat intraocular hypertension.


BACKGROUND OF THE INVENTION

10 Subjects who smoke marijuana have reduced intraocular pressure (Helper et al, J. Am. Med. Assoc., 217:1392 (1971)). The primary psychoactive ingredient in marijuana is known to be delta-9-tetrahydrocannabinol ("THC"). Human experiments involving intravenous administration of
15 pure THC have confirmed the intraocular pressure reduction phenomenon seen with subjects who smoke marijuana (Cooler et al, South. Med. J., 70:954 (1977)). As a result, cannabinoids have been investigated as anti-glaucoma agents.

20 However, use of systemic cannabinoids, such as THC, as anti-glaucoma agents is disadvantageous since they can cause significant adverse psychological and physiological side-effects. In addition, cannabinoids are lipophilic compounds that are very insoluble in
25 water, thus hindering their application as topical ophthalmic pharmaceutical products.

Anandamides are structurally different from cannabinoids, such as THC. The first anandamide discovered (Devane et al, Science, 258:1946 (1992)) is

represented by the following formula, and is known as arachidonyl ethanolamide:



Two other endogenous anandamides were subsequently discovered (Hanus et al, J. Med. Chem., 36:3032 (1993)). Several synthetic analogues have also been made (Felder et al, Proc. Natl. Acad. Sci. USA, 90:7656 (1993); Abadji et al, J. Med. Chem., 37: 1889 (1994); Pinto et al, Pharm. Exp. Therap., 46:516 (1994); and Adams et al, Life Sciences, 56:2041 (1995)).

Arachidonyl ethanolamide is an endogenous porcine ligand reported to bind to the cannabinoid receptor in the brain (Devane et al, *supra*). Like THC, anandamides are useful in reducing intraocular pressure (PCT Patent Publication WO 94/12466). However, it has been discovered in the present invention that many anandamides, when used as a hypotensive agent, have a disadvantage in that a hypertensive effect is induced during the initial phase of action.

Aqueous eyedrops are the most commonly used dosage form for ophthalmic drug delivery. This is because eyedrops are easy to use, relatively inexpensive and do not impair vision. However, the aqueous solubility of anandamides is very poor. Thus, ophthalmic delivery of anandamides in aqueous eyedrops is difficult.

Anandamides are soluble in oil solutions (e.g., castor oil, sesame oil, mineral oil, etc.) and organic solvents (e.g., ethanol, chloroform, etc.). However, these solvents cause harmful side-effects when administered to the eyes. Thus, they are generally not used for ophthalmic drug delivery.

Cyclodextrins ("CDs") are a group of homologous cyclic oligosaccharides consisting of six, seven or eight glucopyranose units, and are respectively called α -, β - or γ -cyclodextrin. It is generally known that CDs can form inclusion complexes with various hydrophobic organic or inorganic compounds, and as a result, increase the solubility or stability of these compounds (Bekers et al, Drug Dev. Ind. Pharm., 17:1503-1549 (1991); and Duchene et al, Drug Dev. Ind. Pharm., 16:2487-2499 (1990)). CDs have also been used to increase the dissolution rate, as well as the bioavailability of various drugs, and to decrease the toxicity of topically applied drugs (Bekers et al, Drug Dev. Ind. Pharm., 17:1503-1549 (1991)).

CDs can be regarded as cone-shaped molecules, where the polar hydroxyl groups of the glucose unit are oriented towards the outside of the structure (Bekers et al, Drug Dev. Ind. Pharm., 17:1503-1549 (1991)). Therefore, the outside of CDs is hydrophilic, whereas the inside of the cavity is hydrophobic in character. The minimum requirement for inclusion complex formation is that the guest molecule must fit, entirely or at least partially, into the CD cavity (Bekers et al, Drug Dev. Ind. Pharm., 17:1503-1549 (1991)).

However, little attention had been paid to the suitability of CDs for use with drugs having ophthalmic activity or for use in ophthalmic compositions. Co-administered CD has increased the

ocular absorption of dexamethasone (Loftsson et al, Int. J. Pharm., 104:181-184 (1994), dexamethasone acetate (Usayapant et al, Pharm. Res., 8:1495-1499 (1991) and pilocarpine (Freedman et al, Curr. Eye Res., 12:641-647 (1993), and the intraocular pressure lowering effect of carbonic anhydrase inhibitors (Loftsson et al, Eur. J. Pharm. Sci., 1:175-180 (1994) (see also EP 326196B1, EP 400637A3, EP 435682A2 and EP 472327A1).

SUMMARY OF THE INVENTION

Accordingly, an object of the present invention is to provide compounds useful for the treatment of elevated intraocular pressure (IOP).


An additional object of the present invention is to provide compounds that possess little or no initial hypertensive effect when used for the treatment of elevated IOP.

Another object of the present invention is to provide an ophthalmic composition useful for the reduction of IOP which is delivered non-systemically to the site of action, thereby enhancing the effect on IOP and minimizing entry into the central nervous system.

A further object of the present invention is to provide a method for reducing IOP using said compounds.

These and other objects of the present invention, which will be apparent from the detailed description of the invention provided hereinafter, have been met, in a one embodiment, by anandamides represented by Formula (I) or Formula (II):

Formula (I):



wherein

Q is N;

R¹ and R² are each H, an alkyl having from 1 to 3
 5 carbon atoms or (CH₂)_a-R³, wherein a is an integer of
 from 0 to 6, preferably 1 to 4, more preferably 2 to
 3, preferably one of R¹ and R² is H or an alkyl having
 from 1 to 3 carbon atoms and the other of R¹ and R² is
 (CH₂)_a-R³;

R³ is:

- (1) C≡N or SH, preferably C≡N;
- (2) a carbocyclic ring having from
 3 to 7 carbon atoms, preferably
 15 phenyl, or a heterocyclic ring
 having from 3 to 7 atoms, at
 least one of which is a
 heteroatom selected from the
 group consisting of N, O and S,
 preferably pyridino or
 20 morpholino;
- (3) R⁴NR⁵, wherein R⁴ and R⁵ are each H
 or (CH₂)_n-CR⁶R⁷R⁸, wherein n is an
 integer of from 0 to 3,
 preferably 0 to 1, and R⁶, R⁷ and
 25 R⁸ are each H or (CH₂)_p-CH₃,
 wherein p is an integer of from
 0 to 3, preferably 0 to 1; or

(4) $\text{NH}-\overset{\text{O}}{\parallel}{\text{C}}-\text{R}^9$, wherein R^9 is H or $(\text{CH}_2)_q-\text{CR}^{10}\text{R}^{11}\text{R}^{12}$, wherein q is an integer of from 0 to 3, preferably from 0 to 1, and R^{10} , R^{11} and R^{12} are each H or $(\text{CH}_2)_r-\text{CH}_3$, wherein r is an integer of from 0 to 3;

R^1 and R^2 may be combined together with Q to form a heterocyclic ring having 3 to 7 atoms, wherein the heterocyclic ring may have an additional heteroatom(s) selected from the group consisting of N, O and S, preferably morpholino;


x is an integer of from 0 to 18, preferably 2 to 5;

y is an integer of from 0 to 8, preferably 2 to 4; and

z is an integer of from 0 to 18, preferably 2 to 5;

wherein $x + y + z \leq 36$, preferably ≤ 24 , more preferably ≤ 18 , most preferably ≤ 12

Formula (II):



Q is N;

$\text{R}^{1'}$ and $\text{R}^{2'}$ are each H, an alkyl having from 1 to 3 carbon atoms or $(\text{R}^{4'}\text{CR}^{5'})-(\text{CH}_2)_a-\text{R}^{3'}$, wherein a' is an integer of from 0 to 5, preferably 0 to 3, more preferably 1 to 2, preferably one of $\text{R}^{1'}$ and $\text{R}^{2'}$ is H or

an alkyl having from 1 to 3 carbon atoms and the other of $R^{1'}$ and $R^{2'}$ is $(R^{4'}CR^{5'})-(CH_2)_a-R^{3'}$;

$R^{3'}$ is:

- 5 (1) OH, SH, $C\equiv CH$, $C\equiv N$, F, Cl, Br or I, preferably SH, more preferably F; even more preferably $C\equiv CH$, most preferably $C\equiv N$;
- 10 (2) a carbocyclic ring having from 3 to 7 carbon atoms, preferably phenyl, or a heterocyclic ring having from 3 to 7 atoms, at least one of which is a heteroatom selected from the group consisting of N, O and S, preferably pyridino or morpholino;
- 15 (3) R^4NR^5 , wherein R^4 and R^5 are each H or $(CH_2)_n-CR^6R^7R^8$, wherein n is an integer of from 0 to 3, preferably 0 to 1, and R^6 , R^7 and R^8 are each H or $(CH_2)_p-CH_3$, wherein p is an integer of from 0 to 3, preferably 0 to 1;
- 20 (4) $NH-\overset{\overset{O}{\parallel}}{C}-R^9$, wherein R^9 is H or $(CH_2)_q-CR^{10}R^{11}R^{12}$, wherein q is an integer of from 0 to 3, preferably from 0 to 1, and R^{10} , R^{11} and R^{12} are each H or $(CH_2)_r-CH_3$, wherein r is an integer of from 0 to 3; or
- 25 (5) $OCR^{13}R^{14}R^{15}$, wherein R^{13} , R^{14} , R^{15} are each H or $(CH_2)_s-CH_3$, wherein s is
- 30

an integer of from 0 to 3,
preferably 0 to 1;

5 $R^{4'}$ and $R^{5'}$ are each H, $(CH_2)_\ell-R^{3'}$, wherein $R^{3'}$ is a carbocyclic ring having from 3 to 7 carbon atoms or a heterocyclic ring having from 3 to 7 atoms, at least one of which is a heteroatom selected from the group consisting of N, O and S, or $(CH_2)_\ell-CR^{6'}R^{7'}R^{8'}$, wherein ℓ is an integer of from 0 to 3, preferably 1, more preferably 0, and $R^{6'}$, $R^{7'}$, and $R^{8'}$ are each H or
10 $(CH_2)_m-CH_3$, wherein m is an integer of from 0 to 3, preferably 0, preferably only one of $R^{4'}$ and $R^{5'}$ is H;

$R^{1'}$ and $R^{2'}$ may be combined together with Q to form a heterocyclic ring having 3 to 7 atoms, wherein the heterocyclic ring may have an additional heteroatom(s)
15 selected from the group consisting of N, O and S, preferably morpholino;

$R^{4'}$ and $R^{5'}$ may be combined together to form a carbocyclic ring having from 3 to 7 carbon atoms, or may be combined with a heteroatom(s) selected from the group consisting of N, O and S to form a heterocyclic
20 ring having from 3 to 7 atoms;

R^4 or R^5 may be combined together with Q to form a heterocyclic ring having from 3 to 7 atoms, wherein the heterocyclic ring may have an additional
25 heteroatom(s) selected from the group consisting of N, O and S;

x is an integer of from 0 to 18, preferably
2 to 5;

y is an integer of from 0 to 8, preferably
2 to 4; and

5 z is an integer of from 0 to 18, preferably
2 to 5;

wherein $x + y + z \leq 36$, preferably ≤ 24 , more
preferably ≤ 18 , most preferably ≤ 12 .

10 In another embodiment, the above-described
objects have been met by an ophthalmic composition for
reducing intraocular pressure comprising an admixture
of a pharmaceutically effective amount of a compound
represented by Formula (I) or Formula (II), and a
cyclodextrin.

15 In still another embodiment, the above-described
objects have been met by a method for treatment of
intraocular hypertension comprising topically
administering a pharmaceutically effective amount of
a compound represented by Formula (I) or Formula (II)
20 to an affected eye in need of such treatment.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A shows the IOP changes in normotensive
pigmented rabbits (treated eyes) after
unilateral ocular administration (25 μ l) of 5.0% (w/v)
25 2-OH-propyl- β -cyclodextrin (O) or 0.9% (w/v) NaCl (●),
mean \pm S.E. (n = 5).

Figure 1B shows the IOP changes in normotensive
pigmented rabbits (untreated eyes) after unilateral
ocular administration (25 μ l) of 5.0% (w/v)
30 2-OH-propyl- β -cyclodextrin (O) or 0.9% (w/v) NaCl (●),
mean \pm S.E. (n = 5).

Figure 2A shows the IOP changes in normotensive
pigmented rabbits (treated eyes) after unilateral
ocular administration (25 μ l) of 12.5% (w/v)

2-OH-propyl- β -cyclodextrin (○) or 0.9% (w/v) NaCl (●),
mean \pm S.E. (n = 6).

5 Figure 2B shows the IOP changes in normotensive pigmented rabbits (untreated eyes) after unilateral ocular administration (25 μ l) of 12.5% (w/v) 2-OH-propyl- β -cyclodextrin (○) or 0.9% (w/v) NaCl (●), mean \pm S.E. (n = 6).

10 Figure 3A shows the IOP changes in normotensive albino rabbits (treated eyes) after unilateral ocular administration (25 μ l) of 30% (w/v) 2-OH-propyl- β -cyclodextrin (○) or 0.9% (w/v) NaCl (●), mean \pm S.E. (n = 4).

15 Figure 3B shows the IOP changes in normotensive albino rabbits (untreated eyes) after unilateral ocular administration (25 μ l) of 30% (w/v) 2-OH-propyl- β -cyclodextrin (○) or 0.9% (w/v) NaCl (●), mean \pm S.E. (n = 4).

20 Figure 4A shows the IOP changes in normotensive pigmented rabbits (treated eyes) after unilateral ocular administration (25 μ l) of 0.25% (w/v) arachidonyl ethanolamide (○) or 0.9% (w/v) NaCl (●), mean \pm S.E. (n = 6).

25 Figure 4B shows the IOP changes in normotensive pigmented rabbits (untreated eyes) after unilateral ocular administration (25 μ l) of 0.25% (w/v) arachidonyl ethanolamide (○) or 0.9% (w/v) NaCl (●), mean \pm S.E. (n = 6).

30 Figure 5A shows the IOP changes in normotensive albino rabbits (treated eyes) after unilateral ocular administration (25 μ l) of 0.25% (w/v) arachidonyl ethanolamide (○) or 0.9% (w/v) NaCl (●), means \pm S.E. (n = 4).

35 Figure 5B shows the IOP changes in normotensive albino rabbits (untreated eyes) after unilateral ocular administration (25 μ l) of 0.25% (w/v)

arachidonyl ethanolamide (○) or 0.9% (w/v) NaCl (●), means ± S.E. (n = 4).

5 Figure 6A shows the IOP changes in normotensive pigmented rabbits (treated eyes) after unilateral ocular administration (25 μl) of 0.25% (w/v) arachidonyl propanolamide (○) or 0.9% (w/v) NaCl (●), mean ± S.E. (n = 6).

10 Figure 6B shows the IOP changes in normotensive pigmented rabbits (untreated eyes) after unilateral ocular administration (25 μl) of 0.25% (w/v) arachidonyl propanolamide (○) or 0.9% (w/v) NaCl (●), mean ± S.E. (n = 6).

15 Figure 7A shows the IOP changes in normotensive pigmented rabbits (treated eyes) after unilateral ocular administration (25 μl) of 0.25% (w/v) arachidonyl fluoroethylamide (○) or 0.9% (w/v) NaCl (●), means ± S.E. (n = 6).

20 Figure 7B shows the IOP changes in normotensive pigmented rabbits (untreated eyes) after unilateral ocular administration (25 μl) of 0.25% (w/v) arachidonyl fluoroethylamide (○) or 0.9% (w/v) NaCl (●), means ± S.E. (n = 5).

25 Figure 8A shows the IOP changes in normotensive pigmented rabbits (treated eyes) after unilateral ocular administration (25 μl) of 0.25% (w/v) arachidonyl methoxyethylamide (○) or 0.9% (w/v) NaCl (●), mean ± S.E. (n = 6).

30 Figure 8B shows the IOP changes in normotensive pigmented rabbits (untreated eyes) after unilateral ocular administration (25 μl) of 0.25% (w/v) arachidonyl methoxyethylamide (○) or 0.9% (w/v) NaCl (●), mean ± S.E. (n = 6).

35 Figure 9A shows the IOP changes in normotensive pigmented rabbits (treated eyes) after unilateral ocular administration (25 μl) of 0.25% (w/v)

arachidonyl ethanethiolamide (○) or 0.9% (w/v) NaCl (●), means ± S.E. (n = 5).

5 Figure 9B shows the IOP changes in normotensive pigmented rabbits (untreated eyes) after unilateral ocular administration (25 μl) of 0.25% (w/v) arachidonyl ethanethiolamide (○) or 0.9% (w/v) NaCl (●), means ± S.E. (n = 5).

10 Figure 10A shows the IOP changes in normotensive pigmented rabbits (treated eyes) after unilateral ocular administration (25 μl) of 0.20% (w/v) arachidonyl β-phenethylamide (○) or 0.9% (w/v) NaCl (●), mean ± S.E. (n = 6).

15 Figure 10B shows the IOP changes in normotensive pigmented rabbits (untreated eyes) after unilateral ocular administration (25 μl) of 0.20% (w/v) arachidonyl β-phenethylamide (○) or 0.9% (w/v) NaCl (●), mean ± S.E. (n = 6).

20 Figure 11A shows the IOP changes in normotensive pigmented rabbits (treated eyes) after unilateral ocular administration (25 μl) of 0.25% (w/v) arachidonyl aminoethylamide (○) or 0.9% (w/v) NaCl (●), mean ± S.E. (n = 6).

25 Figure 11B shows the IOP changes in normotensive pigmented rabbits (untreated eyes) after unilateral ocular administration (25 μl) of 0.25% (w/v) arachidonyl aminoethylamide (○) or 0.9% (w/v) NaCl (●), mean ± S.E. (n = 6).

30 Figure 12A shows the IOP changes in normotensive pigmented rabbits (treated eyes) after unilateral ocular administration (25 μl) of 0.20% (w/v) arachidonyl N,N-dimethylaminoethylamide (○) or 0.9% (w/v) NaCl (●), mean ± S.E. (n = 6).

Figure 12B shows the IOP changes in normotensive pigmented rabbits (untreated eyes) after unilateral

ocular administration (25 μ l) of 0.20% (w/v) arachidonyl N,N-dimethylaminoethylamide (O) or 0.9% (w/v) NaCl (●), mean \pm S.E. (n = 6).

5 Figure 13A shows the IOP changes in normotensive pigmented rabbits (treated eyes) after unilateral ocular administration (25 μ l) of 0.25% (w/v) arachidonyl N-acetylaminoethylamide (O) or 0.9% (w/v) NaCl (●), mean \pm S.E. (n = 6).

10 Figure 13B shows the IOP changes in normotensive pigmented rabbits (untreated eyes) after unilateral ocular administration (25 μ l) of 0.25% (w/v) arachidonyl N-acetylaminoethylamide (O) or 0.9% (w/v) NaCl (●), mean \pm S.E. (n = 6).

15 Figure 14A shows the IOP changes in normotensive pigmented rabbits (treated eyes) after unilateral ocular administration (25 μ l) of 0.25% (w/v) arachidonyl pyridinoethylamide (O) or 0.9% (w/v) NaCl (●), mean \pm S.E. (n = 6).

20 Figure 14B shows the IOP changes in normotensive pigmented rabbits (untreated eyes) after unilateral ocular administration (25 μ l) of 0.25% (w/v) arachidonyl pyridinoethylamide (O) or 0.9% (w/v) NaCl (●), mean \pm S.E. (n = 6).

25 Figure 15A shows the IOP changes in normotensive pigmented rabbits (treated eyes) after unilateral ocular administration (25 μ l) of 0.25% (w/v) arachidonyl propionitrileamide (O) or 0.9% (w/v) NaCl (●), mean \pm S.E. (n = 6).

30 Figure 15B shows the IOP changes in normotensive pigmented rabbits (untreated eyes) after unilateral ocular administration (25 μ l) of 0.25% (w/v) arachidonyl propionitrileamide (O) or 0.9% (w/v) NaCl (●), mean \pm S.E. (n = 6).

35 Figure 16A shows the IOP changes in normotensive pigmented rabbits (treated eyes) after unilateral

ocular administration (25 μ l) of 0.25% (w/v) arachidonyl morpholineamide (O) or 0.9% (w/v) NaCl (\bullet), mean \pm S.E. (n = 6).

5 Figure 16B shows the IOP changes in normotensive pigmented rabbits (untreated eyes) after unilateral ocular administration (25 μ l) of 0.25% (w/v) arachidonyl morpholineamide (O) or 0.9% (w/v) NaCl (\bullet), mean \pm S.E. (n = 6).

10 Figure 17A shows the IOP changes in normotensive pigmented rabbits (treated eyes) after unilateral ocular administration (25 μ l) of 0.25% (w/v) arachidonyl α -dimethylethanolamide (O) or 0.9% (w/v) NaCl (\bullet), mean \pm S.E. (n = 6).

15 Figure 17B shows the IOP changes in normotensive pigmented rabbits (untreated eyes) after unilateral ocular administration (25 μ l) of 0.25% (w/v) arachidonyl α -dimethylethanolamide (O) or 0.9% (w/v) NaCl (\bullet), mean \pm S.E. (n = 6).

20 Figure 18A shows the IOP changes in normotensive pigmented rabbits (treated eyes) after unilateral ocular administration (25 μ l) of 0.25% (w/v) arachidonyl α -isopropylethanolamide (O) or 0.9% (w/v) NaCl (\bullet), mean \pm S.E. (n = 6).

25 Figure 18B shows the IOP changes in normotensive pigmented rabbits (untreated eyes) after unilateral ocular administration (25 μ l) of 0.25% (w/v) arachidonyl α -isopropylethanolamide (O) or 0.9% (w/v) NaCl (\bullet), mean \pm S.E. (n = 6).

30 Figure 19A shows the IOP changes in normotensive pigmented rabbits (treated eyes) after unilateral ocular administration (25 μ l) of 0.20% (w/v) arachidonyl α -phenylethanolamide (O) or 0.9% (w/v) NaCl (\bullet), mean \pm S.E. (n = 6).

35 Figure 19B shows the IOP changes in normotensive pigmented rabbits (untreated eyes) after unilateral


ocular administration (25 μ l) of 0.20% (w/v) arachidonyl α -phenylethanolamide (O) or 0.9% (w/v) NaCl (\bullet), mean \pm S.E. (n = 6).

DETAILED DESCRIPTION OF THE INVENTION

5

As discussed above, anandamides of the present invention are represented by Formula (I) or Formula (II):

Formula (I):



wherein

10

Q is N;

15

R^1 and R^2 are each H, an alkyl having from 1 to 3 carbon atoms or $(\text{CH}_2)_a-\text{R}^3$, wherein a is an integer of from 0 to 6, preferably 1 to 4, more preferably 2 to 3, preferably one of R^1 and R^2 is H or an alkyl having from 1 to 3 carbon atoms, and the other of R^1 and R^2 is $(\text{CH}_2)_a-\text{R}^3$;

R^3 is:

- 5
- 10
- 15
- 20
- 25
- (1) $C\equiv N$ or SH , preferably $C\equiv N$;
 - (2) a carbocyclic ring having from 3 to 7 carbon atoms, preferably phenyl, or a heterocyclic ring having from 3 to 7 atoms, at least one of which is a heteroatom selected from the group consisting of N, O and S, preferably pyridino or morpholino;
 - (3) R^4NR^5 , wherein R^4 and R^5 are each H or $(CH_2)_n-CR^6R^7R^8$, wherein n is an integer of from 0 to 3, preferably 0 to 1, and R^6 , R^7 and R^8 are each H or $(CH_2)_p-CH_3$, wherein p is an integer of from 0 to 3, preferably 0 to 1; or
 - (4) $NH-\overset{O}{\parallel}C-R^9$, wherein R^9 is H or $(CH_2)_q-CR^{10}R^{11}R^{12}$, wherein q is an integer of from 0 to 3, preferably from 0 to 1, and R^{10} , R^{11} and R^{12} are each H or

$(\text{CH}_2)_r\text{-CH}_3$, wherein r is an integer
of from 0 to 3;

R^1 and R^2 may be combined together with Q to form
a heterocyclic ring having 3 to 7 atoms, wherein the
heterocyclic ring may have an additional heteroatom(s)
selected from the group consisting of N, O and S,
preferably morpholino;

x is an integer of from 0 to 18, preferably
2 to 5;


y is an integer of from 0 to 8, preferably
2 to 4; and

z is an integer of from 0 to 18, preferably
2 to 5;

wherein $x + y + z \leq 36$, preferably ≤ 24 , more
preferably ≤ 18 , most preferably ≤ 12 .

Specific non-limiting examples of the compounds
represented by Formula (I) which can be employed in
the present invention include the following:

arachidonyl propionitrileamide



Formula (I):

$\text{R}^1 = (\text{CH}_2)_a\text{-R}^3$; $\text{R}^2 = \text{H}$; $\text{R}^3 = \text{CN}$;


$a = 2$; $x = 3$; $y = 4$; and $z = 3$.

Another example of a compound within the scope of
Formula (I) which can be employed in the present
invention is arachidonyl ethanethiolamide.

Further specific non-limiting examples of the
compounds represented by Formula (I) which can be
employed in the present invention include arachidonyl

β -phenethylamide, arachidonyl N-acetylaminoethylamide, arachidonyl N,N-dimethylaminoethylamide, arachidonyl aminoethylamide, arachidonyl pyridinoethylamide and arachidonyl morpholineamide.

5 As discussed above, the anandamide analogues of the present invention are also represented by Formula (II):



wherein

Q is N;

10

$\text{R}^{1'}$ and $\text{R}^{2'}$ are each H, an alkyl having from 1 to 3 carbon atoms or $(\text{R}^{4'}\text{CR}^{5'})-(\text{CH}_2)_{a'}-\text{R}^{3'}$, wherein a' is an integer of from 0 to 5, preferably 0 to 3, preferably 1 to 2, preferably one of $\text{R}^{1'}$ and $\text{R}^{2'}$ is H or an alkyl having from 1 to 3 carbon atoms and the other of $\text{R}^{1'}$ and $\text{R}^{2'}$ is $(\text{R}^{4'}\text{CR}^{5'})-(\text{CH}_2)_{a'}-\text{R}^{3'}$;

15

$\text{R}^{3'}$ is:

(1) OH, SH, $\text{C}\equiv\text{CH}$, $\text{C}\equiv\text{N}$, F, Cl, Br or I, preferably SH, more preferably F; even more preferably $\text{C}\equiv\text{CH}$, most preferably $\text{C}\equiv\text{N}$;

20

(2) a carbocyclic ring having from 3 to 7 carbon atoms, preferably phenyl, or a heterocyclic ring having from 3 to 7 atoms, at least one of which is a heteroatom selected from the group consisting of N, O and S,

25

preferably pyridino or morpholino;

- (3) R^4NR^5 , wherein R^4 and R^5 are each H or $(CH_2)_n-CR^6R^7R^8$, wherein n is an integer of from 0 to 3, preferably 0 to 1, and R^6 , R^7 and R^8 are each H or $(CH_2)_p-CH_3$, wherein p is an integer of from 0 to 3, preferably 0 to 1;

- (4) $NH-\overset{\overset{O}{\parallel}}{C}-R^9$, wherein R^9 is H or $(CH_2)_q-CR^{10}R^{11}R^{12}$, wherein q is an integer of from 0 to 3, preferably from 0 to 1, and R^{10} , R^{11} and R^{12} are each H or $(CH_2)_r-CH_3$, wherein r is an integer of from 0 to 3; or

- (5) $OCR^{13}R^{14}R^{15}$, wherein R^{13} , R^{14} , R^{15} are each H or $(CH_2)_s-CH_3$, wherein s is an integer of from 0 to 3, preferably 0 to 1;

$R^{4'}$ and $R^{5'}$ are each H, $(CH_2)_l-R^{3'}$, where $R^{3'}$ is a carbocyclic ring having from 3 to 7 carbon atoms, or a heterocyclic ring having from 3 to 7 atoms, at least one of which is a heteroatom selected from the group consisting of N, O and S, or $(CH_2)_l-CR^{6'}R^{7'}R^{8'}$, wherein l is an integer of from 0 to 3, preferably 1, more preferably 0, and $R^{6'}$, $R^{7'}$, and $R^{8'}$ are each H or $(CH_2)_m-CH_3$, wherein m is an integer of from 0 to 3, preferably from 0 to 1, preferably only one of $R^{4'}$ and $R^{5'}$ is H;

$R^{1'}$ and $R^{2'}$ may be combined together with Q to form a heterocyclic ring having 3 to 7 atoms, wherein the heterocyclic ring may have an additional heteroatom(s)

selected from the group consisting of N, O and S,
preferably morpholino;

5 $R^{4'}$ and $R^{5'}$ may be combined together to form a
carbocyclic ring having from 3 to 7 carbon atoms, or
may be combined with a heteroatom(s) selected from the
group consisting of N, O and S to form a heterocyclic
ring having from 3 to 7 atoms;

10 R^4 or R^5 may be combined together with Q to form
a heterocyclic ring having from 3 to 7 atoms, wherein
the heterocyclic ring may have an additional
heteroatom(s) selected from the group consisting of N,
O and S,;

x is an integer of from 0 to 18, preferably
2 to 5;


15 y is an integer of from 0 to 8, preferably
2 to 4; and

z is an integer of from 0 to 18, preferably
2 to 5;

wherein $x + y + z \leq 36$, preferably ≤ 24 , more
preferably ≤ 18 , most preferably ≤ 12 .


Specific non-limiting examples of the compounds
represented by Formula (II) which can be employed in
the present invention include the following:

arachidonyl α -isopropylethanolamide



25 Another example of a compound within the scope of
Formula (II) which can be employed in the present
invention is arachidonyl α -methylethanolamide, which

is described by Felder et al, *supra*, and is a compound of Formula (I), wherein



Further specific non-limiting examples of the compounds represented by Formula (II) which can be employed in the present invention include arachidonyl α -dimethylethanolamide, arachidonyl α -phenylethanolamide, arachidonyl α -iso-butylethanolamide, and arachidonyl α -tert-butylethanolamide.

All of the compounds within Formula (I) and Formula (II) can be synthesized according to the methods of Devane et al, Science, 258:1946 (1992), by utilizing the appropriate fatty acid chloride and amine. In addition, some precursors may be protected/deprotected before/after the formative reaction, by methods well-known in the art (Greene et al, Protective Groups in Organic Synthesis, 2nd Ed., Wiley Interscience, pages 10-143 (1991)).

In the present invention, the insolubility of the compounds represented by Formula (I) or Formula (II) in aqueous solutions has been overcome by the admixture thereof with CDs which do not cause harmful ocular side-effects in patients.

Due to their hydrophilic character and size, CDs are not transported through the cell membranes (Frijlink et al, Int. J. Pharm., 64:195-205 (1990); and Nakanishi et al, Chem. Pharm. Bull., 37:1395-1398 (1989)). In addition, CDs have low general toxicity, and only small amounts are necessary to administer in topical ophthalmic compositions (Doorne, Eur. J. Pharm. Biopharm., 39:133-139 (1993)). For these reasons, little or no side-effects are observed after

topical intraocular administration. Thus, CDs demonstrate great utility as useful adjuvants in the ophthalmic compositions of the present invention.

5 Examples of the cyclodextrin which can be employed in the ophthalmic compositions of the present invention include α -cyclodextrins, β -cyclodextrins and γ -cyclodextrins, and derivatives thereof, such as cyclodextrin ethers (alkyl, e.g., methyl and ethyl, ethers or hydroxyalkyl, e.g., hydroxyethyl and hydroxypropyl, ethers) and esters (acylates, 10 sulfonates, sulfates and phosphates). For ease of formulation (inclusion efficiency), economical reasons and commercial availability, the cyclodextrin is preferably a β -cyclodextrin, more preferably a β -cyclodextrin alkylated or hydroxyalkylated in the 2-, 3- and/or 6-position. Particularly useful β -cyclodextrins include 2-hydroxypropyl- β -cyclodextrin and heptakis-(2,6-di-O-methyl)- β -cyclodextrin.

15 The amount of compound represented by Formula (I) or Formula (II) to be employed in the ophthalmic compositions of the present invention is generally about 0.01 to 2.0% (w/v), preferably about 0.1% to 0.5% (w/v).

20 The amount of cyclodextrin to be employed in the ophthalmic compositions of the present invention is generally about 0.5 to 40% (w/v), preferably about 5.0% to 25% (w/v).

25 The ophthalmic compositions of the present invention are prepared by adding a cyclodextrin to an aqueous solution comprising the compound represented by Formula (I) or Formula (II) so as to form an inclusion complex with the cyclodextrin. As a result, the aqueous solubility of the compound can be increased to a level sufficient for topical 30 intraocular administration, which is undoubtedly

desirable for long-term therapy of intraocular hypertension.

In the present invention, the compounds represented by Formula (I) and Formula (II) are topically delivered non-systemically to the site of action, enhancing the effect, and minimizing entry into the central nervous system.

According to the present invention, after topical administration of, e.g., eyedrops, containing a compound represented by Formula (I) and Formula (II), and a cyclodextrin, the compound is first released from the inclusion complex on the precorneal area where it is then able to penetrate across the cornea to reach the inner eye and the site of action.

It is commonly known that ophthalmic drugs decrease IOP less in normotensive rabbits than in hypertensive (glaucoma) rabbits (Vartiainen et al, Invest. Ophthalmol. Vis. Sci., 33:2019-2023 (1992); and Muchtar et al, Ophthalmic. Res., 24:142-149 (1992)). Generally, the rabbit is the most commonly used animal model in ocular drug research because its eye size is similar to humans, and because rabbits are relatively small and easy to handle (Greaves et al, STP Pharm. Sci., 2:13-33 (1992)).

It was found in the present invention that topical administration of 2-hydroxypropyl- β -cyclodextrin or heptakis-(2,6-di-O-methyl)- β -cyclodextrin in combination with the compounds represented by Formula (I) and Formula (II) are particularly effective in decreasing IOP in treated eyes of normotensive rabbits.

One aspect of the present invention is based on the discovery that unilateral application of the compounds represented by Formula (I) and Formula (II)

decreases the IOP in treated eyes, but does not significantly induce an initial hypertensive effect in normotensive rabbits. Thus, it has been found for the first time in the present invention that these compounds act locally within the eye to lower intraocular pressure without a significant initial hypertensive phase, perhaps via avoidance of spasm to the ciliary muscle surrounding the duct through which the eye fluids drain, and result in the reduction of intraocular pressure.

The ophthalmic compositions of the present invention may also include water-soluble polymeric compounds for use as a viscosity enhancing agent. Examples of such water-soluble polymeric compounds include hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl alcohols, sodium polyacrylate, sodium carboxymethyl cellulose, polyvinyl pyrrolidone, hyaluronic acid and polyacrylic acid.

The viscosity enhancing agents may be used in the ophthalmic compositions of the present invention in amounts which result in a viscosity in the range of about 1 to 1,000 cP, preferably about 5 to 50 cP.

The ophthalmic compositions of the present invention may further comprise a buffering agent, such as acetate, citrate, phosphate and borate buffers, or mixtures of these buffers.

The concentration of the buffering agent which may be used in the ophthalmic compositions of the present invention is in the range of about 1.0 mM to 200 mM, preferably about 10 mM to 100 mM.

The pH of the ophthalmic composition of the present invention should be in the range of about 4.0 to 8.0, and more specifically about 6.0 to 7.4.

5 The ophthalmic compositions of the present invention may also include additional carrier adjuvants, including conventional additives, such as a preservative (e.g., benzalkonium chloride, benzyl alcohol, chlorbutanol, chlorhexidine, etc.) or an antioxidant (e.g., sodium bisulfite, sodium thiosulfite, EDTA, etc.). The concentration of these additives in the composition will be selected according to their type/concentration.

10 The pharmaceutically effective amount of the compound represented by Formula (I) and Formula (II) to be topically administered to the effected eye will generally vary depending upon the age, weight, sex and severity of hypertension in the eye. Typically, the pharmaceutically effective amount will be in the range
15 of about 0.05 to 30 $\mu\text{g}/\text{kg}$ body weight, preferably about 0.5 to 10 $\mu\text{g}/\text{kg}$ body weight.

20 The following examples are provided for illustrative purposes only, and are in no way intended to limit the scope of the present invention.

Comparative Examples 1 to 3 below demonstrate that varying concentrations of cyclodextrins, by themselves, do not act to reduce IOP.

COMPARATIVE EXAMPLE 1

25 In this example, the effect of a 5.0% (w/v) 2-OH-propyl- β -cyclodextrin solution on intraocular pressure (IOP) of normotensive pigmented rabbits (weighing between 2.6-3.6 kg; n = 5) of both sexes was studied. The rabbits were housed separately in cages
30 under standard laboratory conditions, i.e., 10 hr dark/14 hr light cycle.

More specifically, 250 mg of 2-OH-propyl- β -CD was added to 5.0 ml of distilled water, and the solution was adjusted to pH 7.0 with sodium

hydroxide/hydrochloric acid. Then, distilled water was added to adjust the total volume to 5.0 ml. The osmolality of the solution was adjusted to isotonic, 301 mOsm/kg, with sodium chloride.

5 As a control, a 0.9% (w/v) NaCl was also prepared.

10 Then, 25 μ l of the 5.0% (w/v) CD solution or the NaCl solution was administered unilaterally. Again, the rabbits were kept in restraint boxes during the study and IOP was measured using a BioRad (Cambridge, MA) Digilab Modular One Pneumatometer. Before each measurement, one or two drops of 0.06% (w/v) oxybuprocaine were applied to the cornea before tonometry to eliminate discomfort. For each
15 determination at least two readings were taken from each eye. The measurements were started 2 hr before CD or 0.9% (w/v) NaCl solution administration, and were continued 5 hr after administration.

20 The IOPs of the pigmented rabbits at the time of eyedrop administration were between 15.2-21.9 mmHg (n = 5).

The results are shown in Figures 1A and 1B, and Table I below. All of the values are expressed as the mean \pm standard error of means (X \pm S.E.).

TABLE I

Intraocular Pressure Changes (mmHg) at Predetermined Times (h) in Normotensive Pigmented Rabbits After Unilateral Administration of Eyedrops (mean \pm S.E., n=5-6)

Solution	0 h	0.5 h	1 h	2 h	3 h	4 h	5 h
<u>Treated eye</u>							
0.9% NaCl	0 \pm 0	0.8 \pm 0.7	-1.0 \pm 0.8	-0.1 \pm 0.6	0.6 \pm 0.5	-0.2 \pm 0.8	1.5 \pm 0.8
5.0% 2-OH-propyl- β -CD	0 \pm 0	0.4 \pm 0.8	0.2 \pm 1.2	0.4 \pm 0.5	0.2 \pm 0.7	1.4 \pm 1.7	1.5 \pm 1.3
12.5% 2-OH-propyl- β -CD	0 \pm 0	0.0 \pm 1.1	-0.1 \pm 1.3	-0.7 \pm 1.1	0.2 \pm 0.8	0.8 \pm 0.9	2.1 \pm 0.9
0.25% Arachidonyl ethanolamide in 5.0% 2-OH-propyl- β -CD	0 \pm 0	2.5 \pm 1.3	-3.4 \pm 1.0	-5.2 \pm 1.3	-2.6 \pm 1.6	-0.9 \pm 1.5	-0.2 \pm 1.1
<u>Untreated eye (contralateral)</u>							
0.9% NaCl	0 \pm 0	0.6 \pm 0.4	-0.2 \pm 0.8	0.1 \pm 0.5	0.9 \pm 0.6	0.1 \pm 0.7	1.4 \pm 0.5
5.0% 2-OH-propyl- β -CD	0 \pm 0	-1.4 \pm 0.3	-1.3 \pm 0.9	-0.4 \pm 0.6	-1.5 \pm 1.6	0.4 \pm 0.8	0.9 \pm 0.7
12.5% 2-OH-propyl- β -CD	0 \pm 0	-0.6 \pm 1.2	-1.1 \pm 0.7	-1.4 \pm 1.0	0.6 \pm 1.4	0.8 \pm 1.2	0.5 \pm 1.2
0.25% Arachidonyl ethanolamide in 5.0% 2-OH-propyl- β -CD	0 \pm 0	-2.1 \pm 0.3	-1.6 \pm 1.1	-0.3 \pm 1.7	-0.3 \pm 0.5	0.3 \pm 1.8	-0.1 \pm 1.5

As shown in Figures 1A and 1B, and Table I above, the unilateral intraocular administration of a 5.0% (w/v) solution of 2-OH-propyl- β -cyclodextrin alone does not greatly affect the IOP of treated or untreated (contralateral) eyes in normotensive pigmented rabbits when compared to administration of the 0.9% (w/v) NaCl solution.

COMPARATIVE EXAMPLE 2

In this example, the effect of a 12.5% (w/v) 2-OH-propyl- β -cyclodextrin solution on intraocular pressure (IOP) of normotensive pigmented rabbits (weighing between 2.1-3.6 kg; n = 6) of both sexes was studied. The rabbits were housed separately in cages under standard laboratory conditions, i.e., 10 hr dark/14 hr light cycle.

More specifically, 1250 mg of 2-OH-propyl- β -CD was added to 10.0 ml of distilled water, and the solution was adjusted to pH 5.0 with sodium hydroxide/hydrochloric acid. Then, distilled water was added to adjust the total volume to 10 ml. The osmolality of the solution was adjusted to isotonic, 300 mOsm/kg, with sodium chloride.

As a control, a 0.9% (w/v) NaCl was also prepared.

Then, 25 μ l of the 12.5% (w/v) CD solution or the NaCl solution was administered unilaterally. Again, the rabbits were kept in restraint boxes during the study and IOP was measured using a BioRad (Cambridge, MA) Digilab Modular One Pneumatometer. Before each measurement, one or two drops of 0.06% (w/v) oxybuprocaine were applied to the cornea before tonometry to eliminate discomfort. For each determination at least two readings were taken from each eye. The measurements were started 2 hr before

CD or 0.9% (w/v) NaCl solution administration, and were continued 5 hr after administration.

The IOPs of the pigmented rabbits at the time of eyedrop administration were between 18.9-25.7 mmHg (n = 6).

The results are shown in Figures 2A and 2B, and Table I above. All of the values are expressed as the mean \pm standard error of means ($X \pm S.E.$).

As shown in Figures 2A and 2B, and Table I above, the unilateral intraocular administration of a 12.5% (w/v) solution of 2-OH-propyl- β -cyclodextrin alone does not greatly affect the IOP of treated or untreated (contralateral) eyes in normotensive pigmented rabbits when compared to administration of the 0.9% (w/v) NaCl solution.

COMPARATIVE EXAMPLE 3

In this example, the effect of a 30% (w/v) 2-OH-propyl- β -cyclodextrin solution on intraocular pressure (IOP) of normotensive albino (New Zealand strain) rabbits (weighing between 3.3-4.3 kg, n = 4) of both sexes was studied. The rabbits were housed separately in cages under standard laboratory conditions, i.e., 10 hr dark/14 hr light cycle.

More specifically, 3000 mg of 2-OH-propyl- β -CD were added to 10 ml of distilled water, and the solution was adjusted to pH 7.0 with sodium hydroxide/hydrochloric acid. Then, distilled water was added to adjust the total volume to 10 ml. The osmolality of the solution was adjusted to isotonic, 436 mOsm/kg, with sodium chloride.

As a control, a 0.9% (w/v) NaCl was also prepared.

Then, 25 μ l of the 30% (w/v) CD solution or the NaCl solution was administered unilaterally. The

rabbits were kept in restraint boxes during the study, and IOP was measured using a BioRad (Cambridge, MA) Digilab Modular One Pneumatonometer. Before each measurement, one or two drops of 0.06% (w/v) oxybuprocaine were applied to the cornea before tonometry to eliminate discomfort. For each determination at least two readings were taken from each eye. The measurements were started 2 hr before the CD or 0.9% (w/v) NaCl solution administration, and were continued 5 hr after administration.

The IOPs of the albino rabbits at the time of eyedrop administration were between 12.4-23.8 mmHg (n = 4).

The results are shown in Figures 3A and 3B, and Table II below. All of the values are expressed as the mean \pm standard error of means ($X \pm S.E.$).

TABLE II

Intraocular Pressure Changes (mmHg) at Predetermined Times (h) in Normotensive Albino Rabbits After Unilateral Administration of Eyedrops (mean \pm S.E., n=4)

Solution	0 h	0.5 h	1 h	2 h	3 h	4 h	5 h
<u>Treated eye</u>							
0.9% NaCl	0 \pm 0	-0.9 \pm 0.8	-0.3 \pm 0.7	0.8 \pm 1.0	-0.4 \pm 0.4	0.8 \pm 0.4	0.9 \pm 0.9
30% 2-OH-propyl- β -CD	0 \pm 0	0.4 \pm 0.8	-0.5 \pm 1.3	1.2 \pm 0.9	0.5 \pm 1.2	0.7 \pm 1.5	1.7 \pm 1.5
0.25% Arachidonyl ethanolamide in 5.0% 2-OH-propyl- β -CD	0 \pm 0	2.1 \pm 0.9	-1.3 \pm 2.5	-4.4 \pm 1.7	-2.5 \pm 1.2	-0.5 \pm 1.1	-0.6 \pm 0.9
<u>Untreated eye (contralateral)</u>							
0.9% NaCl	0 \pm 0	-1.2 \pm 0.4	-1.7 \pm 0.4	0.0 \pm 0.7	-0.3 \pm 0.6	1.1 \pm 0.7	1.7 \pm 0.8
30% 2-OH-propyl- β -CD	0 \pm 0	-0.1 \pm 0.5	-1.3 \pm 0.6	-0.5 \pm 1.1	-0.9 \pm 0.4	0.2 \pm 1.0	-0.1 \pm 0.7
0.25% Arachidonyl ethanolamide in 5.0% 2-OH-propyl- β -CD	0 \pm 0	-1.1 \pm 0.7	-1.2 \pm 0.6	0.4 \pm 0.7	0.7 \pm 0.8	0.8 \pm 1.4	0.8 \pm 0.5

As shown in Figures 3A and 3B, and Table II above, the unilateral intraocular administration of a 30% (w/v) solution of 2-OH-propyl- β -cyclodextrin alone does not greatly affect the IOP of treated or untreated (contralateral) eyes in normotensive albino rabbits when compared to administration of the 0.9% (w/v) NaCl solution.

Comparative Examples 4 to 6 below demonstrate the initial hypertensive phase present in the action of anandamide and certain analogues thereof, as well as their IOP lowering effects.

COMPARATIVE EXAMPLE 4

In this example, the effect of a 0.25% (w/v) arachidonyl ethanolamide solution on intraocular pressure (IOP) of normotensive pigmented (weighing between 2.1-3.6 kg, n = 6) and albino (New Zealand strain) rabbits (weighing between 3.3-4.3 kg (n = 4)) of both sexes was studied. The rabbits were housed separately in cages under standard laboratory conditions, i.e., 10 hr dark/14 hr light cycle.

More specifically, 12.5 mg of arachidonyl ethanolamide and 250 mg of 2-OH-propyl- β -CD were added to 5.0 ml of distilled water, and the solution was adjusted to pH 7.0 with sodium hydroxide/hydrochloric acid. Then, distilled water was added to adjust the total volume to 5.0 ml. The osmolality of the solution was adjusted to isotonic, 301 mOsm/kg, with sodium chloride.

As a control, a 0.9% (w/v) NaCl was also prepared.

Then, 25 μ l of the drug-CD solution or the NaCl solution was administered unilaterally. Again, the rabbits were kept in restraint boxes during the study, and IOP was measured using a BioRad (Cambridge, MA)

Digilab Modular One Pneumatometer. Also, before each measurement, one or two drops of 0.06% (w/v) oxybuprocaine were applied to the cornea before tonometry to eliminate discomfort. For each
5 determination at least two readings were taken from each eye. The measurements were started 2 hr before drug-CD or 0.9% (w/v) NaCl solution administration, and were continued 5 hr after administration.

The IOPs of pigmented and albino rabbits at the
10 time of eyedrop administration were between 19.6-27.2 mmHg (n = 6) and 12.4-23.8 mmHg (n = 4), respectively.

The results are shown in Figure 4A and 4B, Figures 5A and 5B, and Table I above and Table II
15 above. All of the values are expressed as the mean \pm standard error of means ($X \pm S.E.$).

As shown in Figure 4A and Table I above, unilateral intraocular administration of arachidonyl ethanolamide decreases the IOP in treated eyes in
20 normotensive pigmented rabbits when compared to administration of the 0.9% (w/v) NaCl solution. In the treated eyes of normotensive pigmented rabbits, cyclodextrin vehiculated arachidonyl ethanolamide showed a hypertensive phase during the first 30 min, and a maximal IOP reduction of 5.2 mmHg, 2 hr after
25 0.25% (w/v) arachidonyl ethanolamide treatment.

On the other hand, as shown in Figure 4B and Table I above, unilateral intraocular administration of arachidonyl ethanolamide does not greatly affect
30 the IOP in the contralateral (untreated) eye in normotensive pigmented rabbits when compared to administration of the 0.9% (w/v) NaCl solution. Specifically, in the contralateral eye of normotensive pigmented rabbits, the maximal IOP reduction was

2.1 mmHg, 30 min after 0.25% (w/v) arachidonyl ethanolamide treatment.

5 Similarly, as shown in Figure 5A and Table II above, unilateral intraocular administration of arachidonyl ethanolamide also resulted in a hypertensive peak at 30 min, thereafter decreasing the IOP in treated eyes in normotensive albino rabbits when compared to administration of the 0.9% (w/v) NaCl solution. Specifically, in the treated eyes of 10 normotensive albino rabbits, cyclodextrin vehiculated arachidonyl ethanolamide showed a maximal IOP reduction of 4.4 mmHg, 2 hr after 0.25% (w/v) arachidonyl ethanolamide treatment.

15 However, as shown in Figure 5B and Table II above, no great affect on the IOP in the contralateral (untreated) eye in normotensive albino rabbits was seen when compared to administration of the 0.9% (w/v) NaCl solution. In particular, in the contralateral eye of normotensive pigmented rabbits, the maximal IOP 20 reduction was 1.3 mmHg, 60 min after 0.25% (w/v) arachidonyl ethanolamide treatment.

COMPARATIVE EXAMPLE 5

25 In this example, the effect of a 0.25% (w/v) arachidonyl propanolamide solution on IOP of normotensive pigmented rabbits weighing between 2.6-3.6 kg (n = 6) was studied. The rabbits were housed separately in cages under standard laboratory conditions, i.e., 10 hr dark/14 hr light cycle.

30 More specifically, 12.5 mg of arachidonyl propanolamide and 375 mg of 2-OH-propyl- β -CD were added to distilled water, and the solution was adjusted to pH 7.0 with sodium hydroxide/hydrochloric acid. Then, distilled water was added to adjust the total volume to 5.0 ml. The osmolality of the

solution was adjusted to isotonic, 298 mOsm/kg, with sodium chloride.

As a control, a 0.9% (w/v) NaCl was also prepared.

5 Then, 25 μ l of either the drug-CD solution or the NaCl solution was administered unilaterally to the rabbits. The rabbits were kept in restraint boxes during the study.

10 IOP was measured using a BioRad (Cambridge, MA) Digilab Modular One Pneumatometer. Before each measurement, one or two drops of 0.06% (w/v) oxybuprocaine were applied to the cornea as an anaesthetic before tonometry to eliminate discomfort. For each determination, at least two readings were
15 taken from each eye. The measurements were started 2 hr before drug-CD or 0.9% (w/v) NaCl solution administration, and were continued for 5 hr after administration.

20 The IOPs of the pigmented rabbits at the time of eyedrop administration were between 14.0-29.7 mmHg (n = 6).

The results are shown in Figures 6A and 6B, and Table III below. All of the values are expressed as the mean \pm standard error of means ($X \pm S.E.$).

TABLE III

Intraocular Pressure Changes (mmHg) at Predetermined Times (h) in Normotensive Pigmented Rabbits After Unilateral Administration of Eyedrops (mean \pm S.E., n=5-6)

Solution	0 h	0.5 h	1 h	2 h	3 h	4 h	5 h
<u>Treated eye</u>							
0.9% NaCl	0 \pm 0	0.7 \pm 1.0	1.0 \pm 0.8	-0.3 \pm 0.6	0.6 \pm 1.0	3.5 \pm 1.7	3.2 \pm 1.0
0.25% Arachidonyl propanolamide in 7.5% 2-OH-propyl- β -CD	0 \pm 0	5.4 \pm 3.0	3.6 \pm 2.8	-2.0 \pm 2.2	-2.2 \pm 1.5	-0.1 \pm 1.2	1.1 \pm 1.0
0.25% Arachidonyl fluoroethylamide in 15% in 2-OH-propyl- β -CD	0 \pm 0	1.7 \pm 2.2	0.2 \pm 1.7	-3.7 \pm 0.8	-1.7 \pm 0.6	-0.3 \pm 0.6	-0.5 \pm 0.6
0.25% Arachidonyl ethanethiolamide in 10% 2-OH-propyl- β -CD	0 \pm 0	-0.6 \pm 0.9	-0.9 \pm 1.0	-2.3 \pm 0.4	0.0 \pm 0.0	-2.2 \pm 1.0	-2.4 \pm 0.5
<u>Untreated eye (contralateral)</u>							
0.9% NaCl	0 \pm 0	-1.1 \pm 0.8	1.9 \pm 1.7	1.1 \pm 0.7	-0.3 \pm 1.2	1.9 \pm 1.3	1.9 \pm 0.7
0.25% Arachidonyl propanolamide in 7.5% in 2-OH-propyl- β -CD	0 \pm 0	-0.5 \pm 0.6	-0.9 \pm 0.3	-0.3 \pm 0.9	-1.1 \pm 0.9	0.7 \pm 0.6	2.1 \pm 0.7
0.25% Arachidonyl fluoroethylamide in 15% 2-OH-propyl- β -CD	0 \pm 0	-0.3 \pm 1.2	-0.7 \pm 0.9	-1.2 \pm 1.0	-0.7 \pm 1.0	-1.3 \pm 1.0	0.0 \pm 1.0
0.25% Arachidonyl ethanethiolamide in 10% 2-OH-propyl- β -CD	0 \pm 0	-2.0 \pm 0.6	-0.9 \pm 0.3	-0.1 \pm 1.1	0.0 \pm 0.0	-0.6 \pm 0.8	0.2 \pm 1.0

As shown in Figure 6A and Table III above, unilateral ocular administration of arachidonyl propanolamide decreases the IOP in treated eyes in normotensive pigmented rabbits when compared to administration of a 0.9% (w/v) NaCl solution. In the treated eyes of normotensive pigmented rabbits, cyclodextrin vehiculated arachidonyl propanolamide showed a maximal IOP reduction of 2.2 mmHg, 3 hr after 0.25% (w/v) arachidonyl propanolamide treatment, but preceded by a severe hypertensive phase lasting almost 2 hr.

However, as shown in Figure 6B and Table III above, unilateral ocular administration of arachidonyl propanolamide does not greatly affect the IOP in the contralateral (untreated) eye in normotensive pigmented rabbits when compared to administration of the 0.9% (w/v) NaCl solution. In the contralateral eye of normotensive pigmented rabbits, the maximal IOP reduction was 1.1 mmHg, 3 hr after 0.25% (w/v) arachidonyl propanolamide treatment.

COMPARATIVE EXAMPLE 6

In this example, the effect of a 0.25% (w/v) arachidonyl fluoroethylamide solution on IOP of normotensive pigmented rabbits weighing between 2.6-3.6 kg (n = 6) was studied. The rabbits were housed separately in cages under standard laboratory conditions, i.e., 10 hr dark/14 hr light cycle.

More specifically, 12.5 mg of arachidonyl fluoroethylamide and 750 mg of 2-OH-propyl- β -CD were added to distilled water, and the solution was adjusted to pH 7.0 with sodium hydroxide/hydrochloric acid. Then, distilled water was added to adjust the total volume to 5.0 ml. The osmolality of the

solution was adjusted to isotonic, 310 mOsm/kg, with sodium chloride.

As a control, a 0.9% (w/v) NaCl was also prepared.

5 Then, 25 μ l of either the drug-CD solution or the NaCl solution was administered unilaterally to the rabbits. The rabbits were kept in restraint boxes during the study.

10 IOP was measured using a BioRad (Cambridge, MA) Digilab Modular One Pneumatonometer. Before each measurement, one or two drops of 0.06% (w/v) oxybuprocaine were applied to the cornea as an anaesthetic before tonometry to eliminate discomfort. For each determination, at least two readings were
15 taken from each eye. The measurements were started 2 hr before drug-CD or 0.9% (w/v) NaCl solution administration, and were continued for 5 hr after administration.

20 The IOPs of the pigmented rabbits at the time of eyedrop administration were between 15.2-21.6 mmHg (n = 6).

The results are shown in Figures 7A and 7B, and Table III above. All of the values are expressed as mean \pm standard error of means (X \pm S.E.).

25 As shown in Figure 7A and Table III above, unilateral ocular administration of arachidonyl fluoroethylamide initially increases, and then decreases the IOP in treated eyes in normotensive pigmented rabbits when compared to administration of
30 a 0.9% (w/v) NaCl solution. In the treated eyes of normotensive pigmented rabbits, cyclodextrin vehiculated arachidonyl fluoroethylamide showed a maximal IOP reduction of 3.7 mmHg, 2 hr after 0.25% (w/v) arachidonyl fluoroethylamide treatment.

5 However, as shown in Figure 7B and Table III above, unilateral ocular administration does not greatly affect the IOP in the contralateral (untreated) eye in normotensive pigmented rabbits when compared to administration of the 0.9% (w/v) NaCl solution. In the contralateral eye of normotensive pigmented rabbits, the maximal IOP reduction was 1.2 mmHg, 2 hr after 0.25% (w/v) arachidonyl fluoroethylamide treatment.

10 COMPARATIVE EXAMPLE 7

In this example, the effect of a 0.25% (w/v) arachidonyl methoxyethylamide solution on IOP of normotensive pigmented rabbits weighing between 2.6-3.6 kg (n = 6) was studied. The rabbits were housed separately in cages under standard laboratory conditions, i.e., 10 hr dark/14 hr light cycle.

15 More specifically, 12.5 mg of arachidonyl methoxyethylamide and 750 mg of 2-OH-propyl- β -CD were added to distilled water, and the solution was adjusted to pH 7.0 with sodium hydroxide/hydrochloric acid. Then, distilled water was added to adjust the total volume to 5.0 ml. The osmolality of the solution was adjusted to isotonic, 317 mOsm/kg, with sodium chloride.

20 As a control, a 0.9% (w/v) NaCl was also prepared.

25 Then, 25 μ l of either the drug-CD solution or the NaCl solution was administered unilaterally to the rabbits. The rabbits were kept in restraint boxes during the study.

30 IOP was measured using a BioRad (Cambridge, MA) Digilab Modular One Pneumatometer. Before each measurement, one or two drops of 0.06% (w/v) oxybuprocaine were applied to the cornea as an

anaesthetic before tonometry to eliminate discomfort. For each determination, at least two readings were taken from each eye. The measurements were started 2 hr before drug-CD or 0.9% (w/v) NaCl solution administration, and were continued for 5 hr after administration.

The IOPs of the pigmented rabbits at the time of eyedrop administration were between 22.6-25.9 mmHg (n = 6).

The results are shown in Figures 8A and 8B, and Table IV below. All of the values are expressed as mean \pm standard error of means ($X \pm S.E.$).

TABLE IV

Intraocular Pressure Changes (mmHg) at Predetermined Times (h) in Normotensive Pigmented Rabbits After Unilateral Administration of Eyedrops (mean \pm S.E., n=6)

Solution	0 h	0.5 h	1 h	2 h	3 h	4 h	5 h
<u>Treated eye</u>							
0.9% NaCl	0 \pm 0	0.4 \pm 0.0	0.1 \pm 0.3	-0.4 \pm 0.5	-0.3 \pm 0.4	0.4 \pm 0.3	1.9 \pm 0.6
Arachidonyl methoxyethylamide	0 \pm 0	4.2 \pm 3.0	1.6 \pm 2.0	-1.9 \pm 0.9	-2.0 \pm 0.8	-2.1 \pm 0.7	-1.2 \pm 0.7
Arachidonyl β -phenethylamide	0 \pm 0	1.1 \pm 0.9	-0.1 \pm 0.7	-0.3 \pm 1.2	-1.0 \pm 0.7	-1.0 \pm 0.7	-0.5 \pm 1.0
Arachidonyl aminoethylamide	0 \pm 0	-0.8 \pm 1.0	-2.0 \pm 0.8	-1.5 \pm 0.8	-1.6 \pm 0.8	-0.3 \pm 0.9	-0.1 \pm 1.5
Arachidonyl N,N-dimethylamino ethanamide	0 \pm 0	0.2 \pm 0.3	0.3 \pm 0.5	0.1 \pm 0.7	-0.1 \pm 0.5	-0.8 \pm 0.6	0.6 \pm 0.5
Arachidonyl N-acetyl aminoethylamide	0 \pm 0	0.8 \pm 2.1	-0.1 \pm 1.6	-0.8 \pm 0.5	-0.7 \pm 0.4	-1.0 \pm 0.3	0.2 \pm 0.6
Arachidonyl pyridinoethylamide	0 \pm 0	0.7 \pm 2.2	-0.7 \pm 1.1	-2.2 \pm 0.9	-1.8 \pm 0.6	-1.4 \pm 0.5	-0.9 \pm 0.8
Arachidonyl propionitrileamide	0 \pm 0	0.8 \pm 2.3	-0.7 \pm 2.3	-3.3 \pm 1.3	-3.9 \pm 1.2	-2.1 \pm 0.6	0.5 \pm 0.6
Arachidonyl morpholineamide	0 \pm 0	-0.6 \pm 0.9	-1.4 \pm 0.8	0.1 \pm 0.6	-0.2 \pm 0.8	0.7 \pm 0.6	1.2 \pm 0.5

TABLE IV (Cont.)

Intraocular Pressure Changes (mmHg) at Predetermined Times (h) in Normotensive Pigmented Rabbits After Unilateral Administration of Eyedrops (mean \pm S.E., n=6)

Solution	0h	0.5h	1h	2h	3h	4h	5h
<u>Treated eye (Cont.)</u>							
Arachidonyl α -dimethyl ethanalamide	0 \pm 0	-0.4 \pm 0.4	-1.9 \pm 0.8	-2.5 \pm 0.9	-1.8 \pm 0.7	-0.6 \pm 0.8	1.4 \pm 0.6
Arachidonyl α -isopropyl ethanalamide	0 \pm 0	-1.9 \pm 0.7	-2.7 \pm 0.5	-3.8 \pm 0.6	-3.6 \pm 0.5	-1.4 \pm 0.8	-0.9 \pm 0.6
Arachidonyl α -phenyl ethanalamide	0 \pm 0	-0.1 \pm 0.6	-0.1 \pm 0.6	-0.9 \pm 0.4	-0.5 \pm 0.6	-0.5 \pm 0.7	0.7 \pm 0.6
<u>Untreated eye (contralateral)</u>							
0.9% NaCl	0 \pm 0	0.0 \pm 0.4	0.2 \pm 0.1	-0.3 \pm 0.3	0.2 \pm 0.3	0.9 \pm 0.5	2.0 \pm 0.6
Arachidonyl methoxyethylamide	0 \pm 0	-0.7 \pm 0.5	-1.0 \pm 0.4	-0.4 \pm 0.4	-1.1 \pm 0.5	-0.8 \pm 0.5	0.1 \pm 0.5
Arachidonyl β -phenethylamide	0 \pm 0	-0.1 \pm 0.6	-0.6 \pm 0.6	-0.7 \pm 0.5	-0.9 \pm 0.8	-1.2 \pm 0.5	0.5 \pm 0.8
Arachidonyl aminoethylamide	0 \pm 0	-0.3 \pm 0.6	-1.2 \pm 0.7	-1.1 \pm 0.6	-1.7 \pm 1.0	0.1 \pm 0.7	0.5 \pm 1.2
Arachidonyl N,N-dimethylamino ethanalamide	0 \pm 0	-0.4 \pm 0.2	-0.6 \pm 0.5	-0.8 \pm 0.4	-1.2 \pm 0.6	-1.0 \pm 0.5	0.5 \pm 0.8

TABLE IV (Cont.)

Intraocular Pressure Changes (mmHg) at Predetermined Times (h) in Normotensive Pigmented Rabbits After Unilateral Administration of Eyedrops (mean \pm S.E., n=6)

Solution	0h	0.5h	1h	2h	3h	4h	5h
<u>Untreated eye (contralateral) (Cont.)</u>							
Arachidonyl N-acetyl aminoethylamide	0 \pm 0	-1.1 \pm 0.7	-1.4 \pm 0.5	-1.0 \pm 0.6	-1.3 \pm 0.5	-0.7 \pm 0.4	0.1 \pm 0.6
Arachidonyl pyridinoethylamide	0 \pm 0	-0.8 \pm 0.6	-1.6 \pm 0.8	-1.9 \pm 0.8	-1.9 \pm 0.7	-1.4 \pm 0.8	-0.9 \pm 1.2
Arachidonyl propionitrileamide	0 \pm 0	-0.9 \pm 0.5	-2.0 \pm 0.6	-1.2 \pm 0.7	-2.1 \pm 0.7	-1.5 \pm 0.4	0.3 \pm 0.6
Arachidonyl morpholineamide	0 \pm 0	-0.7 \pm 0.7	-0.4 \pm 0.6	0.2 \pm 0.3	-1.1 \pm 0.4	0.0 \pm 0.3	0.4 \pm 0.3
Arachidonyl α -dimethyl ethanolamide	0 \pm 0	-0.6 \pm 0.5	-1.4 \pm 0.4	-1.7 \pm 1.0	-1.4 \pm 0.8	-0.3 \pm 1.0	1.1 \pm 0.5
Arachidonyl α -isopropyl ethanolamide	0 \pm 0	-1.0 \pm 0.6	-1.7 \pm 0.6	-3.0 \pm 0.6	-3.7 \pm 0.4	-1.2 \pm 0.7	-0.8 \pm 0.3
Arachidonyl α -phenyl ethanolamide	0 \pm 0	-0.4 \pm 0.6	0.2 \pm 0.7	-0.9 \pm 1.0	-1.4 \pm 0.7	-0.2 \pm 0.8	0.7 \pm 0.5

As shown in Figure 8A and Table IV above, unilateral ocular administration of arachidonyl methoxyethylamide decreases the IOP in treated eyes in normotensive pigmented rabbits when compared to administration of a 0.9% (w/v) NaCl solution. In the treated eyes of normotensive pigmented rabbits, cyclodextrin vehiculated arachidonyl methoxyethylamide showed a severe IOP increase lasting approximately 90 min before the maximal IOP reduction of 2.1 mmHg, 4 hr after 0.25% (w/v) arachidonyl methoxyethylamide treatment.

However, as shown in Figure 8B and Table IV above, unilateral ocular administration does not greatly affect the IOP in the contralateral (untreated) eye in normotensive pigmented rabbits when compared to administration of the 0.9% (w/v) NaCl solution. In the contralateral eye of normotensive pigmented rabbits, the maximal IOP reduction was 1.1 mmHg, 3 hr after 0.25% (w/v) arachidonyl methoxyethylamide treatment.

The results in the foregoing examples clearly demonstrate that unilateral intraocular administration of a fatty acid alkanol amide of the type taught in PCT WO 94/12466, such as arachidonyl ethanolamide or arachidonyl propanolamide, in a cyclodextrin, as well as other anandamides, such as arachidonyl fluoroethylamide and arachidonyl methoxyethylamide, decreases the IOP in treated eyes in normotensive pigmented (Figs. 4A, 6A, 7A and 8A, and Tables I, III and IV) and albino rabbits (Fig. 5A and Table II) when compared to administration of the 0.9% (w/v) NaCl solution, but induces an initial hypertensive peak of a potentially deleterious nature when employed clinically. In the treated eyes of normotensive pigmented rabbits, cyclodextrin vehiculated

arachidonyl ethanolamide showed an IOP rise of 2.5 mmHg at 30 min, and then a maximal IOP reduction of 5.2 mmHg, 2 hr after 0.25% (w/v) arachidonyl ethanolamide treatment. The maximal IOP reduction in normotensive albino rabbits was 4.4 mmHg, 2 hr after 0.25% (w/v) arachidonyl ethanolamide treatment, but preceded by a similar (2.1 mmHg) hypertensive phase.

In the treated eyes of normotensive pigmented rabbits, cyclodextrin vehiculated arachidonyl methoxyethylamide showed an IOP elevation (maximum 4.2 mmHg) for more than 1 hr after 0.25% (w/v) arachidonyl methoxyethylamide treatment, and arachidonyl propanolamide showed an IOP elevation (maximum 5.4 mmHg) for almost 2 hr after 0.25% (w/v) arachidonyl propanolamide treatment.

Furthermore, these results show that the unilateral ocular administration of 2-OH-propyl- β -cyclodextrin (5.0% (w/v), 12.5% (w/v) and 30% (w/v)) alone does not affect the IOP of treated or untreated (contralateral) eyes in normotensive rabbits (Figs. 1A, 1B, 2A, 2B, 3A and 3B; and Tables I and II) when compared to administration of the 0.9% (w/v) NaCl solution.

Moreover, the results show that with cyclodextrins it is possible to achieve effective ocular delivery of very lipophilic and water-insoluble compounds, like anandamides, from aqueous eye drop formulations. The cyclodextrins increase the ocular bioavailability of anandamides by increasing the aqueous solubility of anandamides in solution and in the tear-fluid on the precorneal area. The concentration and type of cyclodextrin in the composition of the present invention can be readily selected according to a concentration and type of anandamide employed.

Examples 1 to 8 below demonstrate that certain modifications of the terminal amide moiety, according to Formula (I), ameliorate the characteristic hypertensive phase seen by the above anandamides.

5

EXAMPLE 1

10

In this example, the effect of a 0.25% (w/v) arachidonyl ethanethiolamide solution on IOP of normotensive pigmented rabbits weighing between 2.6-3.6 kg (n = 5) was studied. The rabbits were housed separately in cages under standard laboratory conditions, i.e., 10 hr dark/14 hr light cycle.

15

More specifically, 12.5 mg of arachidonyl ethanethiolamide and 500 mg of 2-OH-propyl- β -CD were added to distilled water, and the solution was adjusted to pH 7.0 with sodium hydroxide/hydrochloric acid. Then, distilled water was added to adjust the total volume to 5.0 ml. The osmolality of the solution was adjusted to isotonic, 325 mOsm/kg, with sodium chloride.

20

As a control, a 0.9% (w/v) NaCl was also prepared.

25

Then, 25 μ l of either the drug-CD solution or the NaCl solution was administered unilaterally to the rabbits. The rabbits were kept in restraint boxes during the study.

30

IOP was measured using a BioRad (Cambridge, MA) Digilab Modular One Pneumatometer. Before each measurement, one or two drops of 0.06% (w/v) oxybuprocaine were applied to the cornea as an anaesthetic before tonometry to eliminate discomfort. For each determination, at least two readings were taken from each eye. The measurements were started 2 hr before drug-CD or 0.9% (w/v) NaCl solution

administration, and were continued for 5 hr after administration.

The IOPs of the pigmented rabbits at the time of eyedrop administration were between 17.1-27.7 mmHg (n = 5).

The results are shown in Figures 9A and 9B, and Table III above. All of the values are expressed as mean \pm standard error of means ($X \pm S.E.$).

As shown in Figure 9A and Table III above, unilateral ocular administration of arachidonyl ethanethiolamide decreases the IOP in treated eyes in normotensive pigmented rabbits when compared to administration of a 0.9% (w/v) NaCl solution. In the treated eyes of normotensive pigmented rabbits, cyclodextrin vehiculated arachidonyl ethanethiolamide showed a maximal IOP reduction of 2.4 mmHg, 5 hr after 0.25% (w/v) arachidonyl ethanethiolamide treatment.

However, as shown in Figure 9B and Table III above, unilateral ocular administration does not greatly affect the IOP in the contralateral (untreated) eye in normotensive pigmented rabbits when compared to administration of the 0.9% (w/v) NaCl solution. In the contralateral eye of normotensive pigmented rabbits, the maximal IOP reduction was 2.0 mmHg, 30 min after 0.25% (w/v) arachidonyl ethanethiolamide treatment.

EXAMPLE 2

In this example, the effect of a 0.20% (w/v) arachidonyl β -phenethylamide solution on the IOP of normotensive pigmented rabbits weighing between 2.6-3.6 kg (n = 6) was studied. The rabbits were housed separately in cages under standard laboratory conditions, i.e., 10 hr dark/14 hr light cycle.

More specifically, 10 mg of arachidonyl β -phenethylamide and 1000 mg of 2-OH-propyl- β -CD were added to distilled water, and the solution was adjusted to pH 7.0 with sodium hydroxide/hydrochloric acid. Then, distilled water was added to adjust the total volume to 5.0 ml. The osmolality of the solution was adjusted to isotonic, 310 mOsm/kg, with sodium chloride.

As a control, a 0.9% (w/v) NaCl was also prepared.

Then, 25 μ l of either the drug-CD solution or the NaCl solution was administered unilaterally to the rabbits. The rabbits were kept in restraint boxes during the study.

IOP was measured using a BioRad (Cambridge, MA) Digilab Modular One Pneumatometer. Before each measurement, one or two drops of 0.06% (w/v) oxybuprocaine were applied to the cornea as an anaesthetic before tonometry to eliminate discomfort. For each determination, at least two readings were taken from each eye. The measurements were started 2 hr before drug-CD or 0.9% (w/v) NaCl solution administration, and were continued for 5 hr after administration.

The IOPs of the pigmented rabbits at the time of eyedrop administration were between 19.5-28.6 mmHg (n = 6).

The results are shown in Figures 10A and 10B, and Table IV above. All of the values are expressed as mean \pm standard error of means ($X \pm S.E.$).

As shown in Figure 10A and Table IV above, unilateral ocular administration of arachidonyl β -phenethylamide decreases the IOP in treated eyes in normotensive pigmented rabbits when compared to administration of a 0.9% (w/v) NaCl solution. In the

5 treated eyes of normotensive pigmented rabbits, cyclodextrin vehiculated arachidonyl β -phenethylamide showed a maximal IOP reduction of 1.0 mmHg, 3-4 hr after 0.2% (w/v) arachidonyl β -phenethylamide treatment.

10 However, as shown in Figure 10B and Table IV above, unilateral ocular administration does affect also the IOP in the contralateral (untreated) eye in normotensive pigmented rabbits when compared to administration of the 0.9% (w/v) NaCl solution. In the contralateral eye of normotensive pigmented rabbits, the maximal IOP reduction was 1.2 mmHg, 4 hr after 0.2% (w/v) arachidonyl β -phenethylamide treatment.

15 EXAMPLE 3

In this example, the effect of a 0.25% (w/v) arachidonyl aminoethylamide solution on IOP of normotensive pigmented rabbits weighing between 2.6-3.6 kg (n = 6) was studied. The rabbits were housed separately in cages under standard laboratory conditions, i.e., 10 hr dark/14 hr light cycle.

20 More specifically, 12.5 mg of arachidonyl aminoethylamide and 1000 mg of 2-OH-propyl- β -CD were added to distilled water, and the solution was adjusted to pH 7.0 with sodium hydroxide/hydrochloric acid. Then, distilled water was added to adjust the total volume to 5.0 ml. The osmolality of the solution was adjusted to isotonic, 390 mOsm/kg, with sodium chloride.

25 As a control, a 0.9% (w/v) NaCl was also prepared.

30 Then, 25 μ l of either the drug-CD solution or the NaCl solution was administered unilaterally to the

rabbits. The rabbits were kept in restraint boxes during the study.

IOP was measured using a BioRad (Cambridge, MA) Digilab Modular One Pneumatometer. Before each measurement, one or two drops of 0.06% (w/v) oxybuprocaine were applied to the cornea as an anaesthetic before tonometry to eliminate discomfort. For each determination, at least two readings were taken from each eye. The measurements were started 2 hr before drug-CD or 0.9% (w/v) NaCl solution administration, and were continued for 5 hr after administration.

The IOPs of the pigmented rabbits at the time of eyedrop administration were between 21.7-26.4 mmHg (n = 6).

The results are shown in Figures 11A and 11B, and Table IV above. All of the values are expressed as mean \pm standard error of means ($X \pm S.E.$).

As shown in Figure 11A and Table IV above, unilateral ocular administration of arachidonyl aminoethylamide decreases the IOP in treated eyes in normotensive pigmented rabbits when compared to administration of a 0.9% (w/v) NaCl solution. In the treated eyes of normotensive pigmented rabbits, cyclodextrin vehiculated arachidonyl aminoethylamide showed a maximal IOP reduction of 2.0 mmHg, 1 hr after 0.25% (w/v) arachidonyl aminoethylamide treatment.

However, as shown in Figure 11B and Table IV above, unilateral ocular administration does affect also the IOP in the contralateral (untreated) eye in normotensive pigmented rabbits when compared to administration of the 0.9% (w/v) NaCl solution. In the contralateral eye of normotensive pigmented rabbits, the maximal IOP reduction was 1.7 mmHg, 3 hr

after 0.25% (w/v) arachidonyl aminoethylamide treatment.

EXAMPLE 4

5 In this example, the effect of a 0.20% (w/v) arachidonyl N,N-dimethylaminoethylamide solution on IOP of normotensive pigmented rabbits weighing between 2.6-3.6 kg (n = 6) was studied. The rabbits were housed separately in cages under standard laboratory conditions, i.e., 10 hr dark/14 hr light cycle.

10 More specifically, 10.0 mg of arachidonyl N,N-dimethylaminoethylamide and 1250 mg of 2-OH-propyl- β -CD were added to distilled water, and the solution was adjusted to pH 7.0 with sodium hydroxide/hydrochloric acid. Then, distilled water was added to adjust the total volume to 5.0 ml. The osmolality of the solution was adjusted to isotonic, 303 mOsm/kg, with sodium chloride.

15 As a control, a 0.9% (w/v) NaCl was also prepared.

20 Then, 25 μ l of either the drug-CD solution or the NaCl solution was administered unilaterally to the rabbits. The rabbits were kept in restraint boxes during the study.

25 IOP was measured using a BioRad (Cambridge, MA) Digilab Modular One Pneumatometer. Before each measurement, one or two drops of 0.06% (w/v) oxybuprocaine were applied to the cornea as an anaesthetic before tonometry to eliminate discomfort. For each determination, at least two readings were taken from each eye. The measurements were started 30 2 hr before drug-CD or 0.9% (w/v) NaCl solution administration, and were continued for 5 hr after administration.

The IOPs of the pigmented rabbits at the time of eyedrop administration were between 19.9-25.6 mmHg (n = 6).

5 The results are shown in Figures 12A and 12B, and Table IV above. All of the values are expressed as mean \pm standard error of means ($X \pm S.E.$).

10 As shown in Figure 12A and Table IV above, unilateral ocular administration of arachidonyl N,N-dimethylaminoethylamide decreases the IOP in treated eyes in normotensive pigmented rabbits when compared to administration of a 0.9% (w/v) NaCl solution. In the treated eyes of normotensive pigmented rabbits, cyclodextrin vehiculated arachidonyl N,N-dimethylaminoethylamide showed a
15 maximal IOP reduction of 0.8 mmHg, 4 hr after 0.2% (w/v) arachidonyl N,N-dimethylaminoethylamide treatment.

20 However, as shown in Figure 12B and Table IV above, unilateral ocular administration does affect also the IOP in the contralateral (untreated) eye in normotensive pigmented rabbits when compared to administration of the 0.9% (w/v) NaCl solution. In the contralateral eye of normotensive pigmented rabbits, the maximal IOP reduction was 1.2 mmHg, 3 hr
25 after 0.2% (w/v) arachidonyl N,N-dimethylaminoethylamide treatment.

EXAMPLE 5

30 In this example, the effect of a 0.25% (w/v) arachidonyl N-acetylaminoethylamide solution on IOP of normotensive pigmented rabbits weighing between 2.6-3.6 kg (n = 6) was studied. The rabbits were housed separately in cages under standard laboratory conditions, i.e., 10 hr dark/14 hr light cycle.

More specifically, 12.5 mg of arachidonyl N-acetylaminoethylamide and 500 mg of 2-OH-propyl- β -CD were added to distilled water, and the solution was adjusted to pH 7.0 with sodium hydroxide/hydrochloric acid. Then, distilled water was added to adjust the total volume to 5.0 ml. The osmolality of the solution was adjusted to isotonic, 303 mOsm/kg, with sodium chloride.

As a control, a 0.9% (w/v) NaCl was also prepared.

Then, 25 μ l of either the drug-CD solution or the NaCl solution was administered unilaterally to the rabbits. The rabbits were kept in restraint boxes during the study.

IOP was measured using a BioRad (Cambridge, MA) Digilab Modular One Pneumatometer. Before each measurement, one or two drops of 0.06% (w/v) oxybuprocaine were applied to the cornea as an anaesthetic before tonometry to eliminate discomfort. For each determination, at least two readings were taken from each eye. The measurements were started 2 hr before drug-CD or 0.9% (w/v) NaCl solution administration, and were continued for 5 hr after administration.

The IOPs of the pigmented rabbits at the time of eyedrop administration were between 21.0-26.2 mmHg (n = 6).

The results are shown in Figures 13A and 13B, and Table IV above. All of the values are expressed as mean \pm standard error of means (X \pm S.E.).

As shown in Figure 13A and Table IV above, unilateral ocular administration of arachidonyl N-acetylaminoethylamide decreases the IOP in treated eyes in normotensive pigmented rabbits when compared to administration of a 0.9% (w/v) NaCl solution. In

the treated eyes of normotensive pigmented rabbits, cyclodextrin vehiculated arachidonyl N-acetylaminoethylamide showed a maximal IOP reduction of 1.0 mmHg, 4 hr after 0.25% (w/v) arachidonyl N-acetylaminoethylamide treatment.

However, as shown in Figure 13B and Table IV above, unilateral ocular administration does affect also the IOP in the contralateral (untreated) eye in normotensive pigmented rabbits when compared to administration of the 0.9% (w/v) NaCl solution. In the contralateral eye of normotensive pigmented rabbits, the maximal IOP reduction was 1.4 mmHg, 1 hr after 0.25% (w/v) arachidonyl N-acetylaminoethylamide treatment.

EXAMPLE 6

In this example, the effect of a 0.25% (w/v) arachidonyl pyridinoethylamide solution on IOP of normotensive pigmented rabbits weighing between 2.6-3.6 kg (n = 6) was studied. The rabbits were housed separately in cages under standard laboratory conditions, i.e., 10 hr dark/14 hr light cycle.

More specifically, 12.5 mg of arachidonyl pyridinoethylamide and 1000 mg of 2-OH-propyl- β -CD were added to distilled water, and the solution was adjusted to pH 7.0 with sodium hydroxide/hydrochloric acid. Then, distilled water was added to adjust the total volume to 5.0 ml. The osmolality of the solution was adjusted to isotonic, 315 mOsm/kg, with sodium chloride.

As a control, a 0.9% (w/v) NaCl was also prepared.

Then, 25 μ l of either the drug-CD solution or the NaCl solution was administered unilaterally to the

rabbits. The rabbits were kept in restraint boxes during the study.

IOP was measured using a BioRad (Cambridge, MA) Digilab Modular One Pneumatometer. Before each measurement, one or two drops of 0.06% (w/v) oxybuprocaine were applied to the cornea as an anaesthetic before tonometry to eliminate discomfort. For each determination, at least two readings were taken from each eye. The measurements were started 2 hr before drug-CD or 0.9% (w/v) NaCl solution administration, and were continued for 5 hr after administration.

The IOPs of the pigmented rabbits at the time of eyedrop administration were between 21.5-30.2 mmHg (n = 6).

The results are shown in Figures 14A and 14B, and Table IV above. All of the values are expressed as mean \pm standard error of means ($X \pm S.E.$).

As shown in Figure 14A and Table IV above, unilateral ocular administration of arachidonyl pyridinoethylamide decreases the IOP in treated eyes in normotensive pigmented rabbits when compared to administration of a 0.9% (w/v) NaCl solution. In the treated eyes of normotensive pigmented rabbits, cyclodextrin vehiculated arachidonyl pyridinoethylamide showed a maximal IOP reduction of 2.2 mmHg, 2 hr after 0.25% (w/v) arachidonyl pyridinoethylamide treatment.

However, as shown in Figure 14B and Table IV above, unilateral ocular administration does affect also the IOP in the contralateral (untreated) eye in normotensive pigmented rabbits when compared to administration of the 0.9% (w/v) NaCl solution. In the contralateral eye of normotensive pigmented rabbits, the maximal IOP reduction was 1.9 mmHg,

2-3 hr after 0.25% (w/v) arachidonyl pyridinoethylamide treatment.

EXAMPLE 7

5 In this example, the effect of a 0.25% (w/v) arachidonyl propionitrileamide solution on IOP of normotensive pigmented rabbits weighing between 2.6-3.6 kg (n = 6) was studied. The rabbits were housed separately in cages under standard laboratory conditions, i.e., 10 hr dark/14 hr light cycle.

10 More specifically, 12.5 mg of arachidonyl propionitrileamide and 1000 mg of 2-OH-propyl- β -CD were added to distilled water, and the solution was adjusted to pH 7.0 with sodium hydroxide/hydrochloric acid. Then, distilled water was added to adjust the total volume to 5.0 ml. The osmolality of the solution was adjusted to isotonic, 302 mOsm/kg, with sodium chloride.

15 As a control, a 0.9% (w/v) NaCl was also prepared.

20 Then, 25 μ l of either the drug-CD solution or the NaCl solution was administered unilaterally to the rabbits. The rabbits were kept in restraint boxes during the study.

25 IOP was measured using a BioRad (Cambridge, MA) Digilab Modular One Pneumatometer. Before each measurement, one or two drops of 0.06% (w/v) oxybuprocaine were applied to the cornea as an anaesthetic before tonometry to eliminate discomfort. For each determination, at least two readings were taken from each eye. The measurements were started 30 2 hr before drug-CD or 0.9% (w/v) NaCl solution administration, and were continued for 5 hr after administration.

The IOPs of the pigmented rabbits at the time of eyedrop administration were between 23.0-30.4 mmHg (n = 6).

The results are shown in Figures 15A and 15B, and Table IV above. All of the values are expressed as mean \pm standard error of means ($X \pm S.E.$).

As shown in Figure 15A and Table IV above, unilateral ocular administration of arachidonyl propionitrileamide decreases the IOP in treated eyes in normotensive pigmented rabbits when compared to administration of a 0.9% (w/v) NaCl solution. In the treated eyes of normotensive pigmented rabbits, cyclodextrin vehiculated arachidonyl propionitrileamide showed a maximal IOP reduction of 3.9 mmHg, 3 hr after 0.25% (w/v) arachidonyl propionitrileamide treatment.

However, as shown in Figure 15B and Table IV above, unilateral ocular administration does affect also the IOP in the contralateral (untreated) eye in normotensive pigmented rabbits when compared to administration of the 0.9% (w/v) NaCl solution. In the contralateral eye of normotensive pigmented rabbits, the maximal IOP reduction was 2.0 mmHg, 1 hr after 0.25% (w/v) arachidonyl propionitrileamide treatment.

EXAMPLE 8

In this example, the effect of a 0.25% (w/v) arachidonyl morpholineamide solution on IOP of normotensive pigmented rabbits weighing between 2.6-3.6 kg (n = 6) was studied. The rabbits were housed separately in cages under standard laboratory conditions, i.e., 10 hr dark/14 hr light cycle.

More specifically, 12.5 mg of arachidonyl morpholineamide and 1000 mg of 2-OH-propyl- β -CD were

added to distilled water, and the solution was adjusted to pH 7.0 with sodium hydroxide/hydrochloric acid. Then, distilled water was added to adjust the total volume to 5.0 ml. The osmolality of the solution was adjusted to isotonic, 315 mOsm/kg, with sodium chloride.

As a control, a 0.9% (w/v) NaCl was also prepared.

Then, 25 μ l of either the drug-CD solution or the NaCl solution was administered unilaterally to the rabbits. The rabbits were kept in restraint boxes during the study.

IOP was measured using a BioRad (Cambridge, MA) Digilab Modular One Pneumatometer. Before each measurement, one or two drops of 0.06% (w/v) oxybuprocaine were applied to the cornea as an anaesthetic before tonometry to eliminate discomfort. For each determination, at least two readings were taken from each eye. The measurements were started 2 hr before drug-CD or 0.9% (w/v) NaCl solution administration, and were continued for 5 hr after administration.

The IOPs of the pigmented rabbits at the time of eyedrop administration were between 21.3-25.5 mmHg (n = 6).

The results are shown in Figures 16A and 16B, and Table IV above. All of the values are expressed as mean \pm standard error of means (X \pm S.E.).

As shown in Figure 16A and Table IV above, unilateral ocular administration of arachidonyl morpholineamide decreases the IOP in treated eyes in normotensive pigmented rabbits when compared to administration of a 0.9% (w/v) NaCl solution. In the treated eyes of normotensive pigmented rabbits, cyclodextrin vehiculated arachidonyl morpholineamide

showed a maximal IOP reduction of 1.4 mmHg, 2 hr after 0.25% (w/v) arachidonyl morpholineamide treatment.

However, as shown in Figure 16B and Table IV above, unilateral ocular administration does affect also the IOP in the contralateral (untreated) eye in normotensive pigmented rabbits when compared to administration of the 0.9% (w/v) NaCl solution. In the contralateral eye of normotensive pigmented rabbits, the maximal IOP reduction was 1.1 mmHg, 2 hr after 0.25% (w/v) arachidonyl morpholineamide treatment.

Examples 9 to 11 below demonstrate that certain modifications of the carbon α to the amide nitrogen, according to Formula (II), eliminate the characteristic hypertensive phase seen by anandamides with alkylamide groups terminated by moieties which are not within the scope of Formula (I).

EXAMPLE 9

In this example, the effect of a 0.25% (w/v) arachidonyl α -dimethylethanolamide solution on IOP of normotensive pigmented rabbits weighing between 2.6-3.6 kg (n = 6) was studied. The rabbits were housed separately in cages under standard laboratory conditions, i.e., 10 hr dark/14 hr light cycle.

More specifically, 12.5 mg of arachidonyl α -dimethylethanolamide and 1000 mg of 2-OH-propyl- β -CD were added to distilled water, and the solution was adjusted to pH 7.0 with sodium hydroxide/hydrochloric acid. Then, distilled water was added to adjust the total volume to 5.0 ml. The osmolality of the solution was adjusted to isotonic, 321 mOsm/kg, with sodium chloride.

As a control, a 0.9% (w/v) NaCl was also prepared.

Then, 25 μ l of either the drug-CD solution or the NaCl solution was administered unilaterally to the rabbits. The rabbits were kept in restraint boxes during the study.

5 IOP was measured using a BioRad (Cambridge, MA) Digilab Modular One Pneumatometer. Before each measurement, one or two drops of 0.06% (w/v) oxybuprocaine were applied to the cornea as an anaesthetic before tonometry to eliminate discomfort. 10 For each determination, at least two readings were taken from each eye. The measurements were started 2 hr before drug-CD or 0.9% (w/v) NaCl solution administration, and were continued for 5 hr after administration.

15 The IOPs of the pigmented rabbits at the time of eyedrop administration were between 19.6-28.9 mmHg (n = 6).

The results are shown in Figures 17A and 17B, and Table IV below. All of the values are expressed as mean \pm standard error of means ($X \pm S.E.$). 20

As shown in Figure 17A and Table IV above, unilateral ocular administration of arachidonyl α -dimethylethanolamide decreases the IOP in treated eyes in normotensive pigmented rabbits when compared 25 to administration of a 0.9% (w/v) NaCl solution. In the treated eyes of normotensive pigmented rabbits, cyclodextrin vehiculated arachidonyl α -dimethylethanolamide showed a maximal IOP reduction of 2.5 mmHg, 2 hr after 0.25% (w/v) arachidonyl 30 α -dimethylethanolamide treatment.

However, as shown in Figure 17B and Table IV above, unilateral ocular administration does affect also on IOP in the contralateral (untreated) eye in normotensive pigmented rabbits when compared to 35 administration of the 0.9% (w/v) NaCl solution. In

the contralateral eye of normotensive pigmented rabbits, the maximal IOP reduction was 1.7 mmHg, 2 hr after 0.25% (w/v) arachidonyl α -dimethylethanolamide treatment.

5

EXAMPLE 10

10

In this example, the effect of a 0.25% (w/v) arachidonyl α -isopropylethanolamide solution on IOP of normotensive pigmented rabbits weighing between 2.6-3.6 kg (n = 6) was studied. The rabbits were housed separately in cages under standard laboratory conditions, i.e., 10 hr dark/14 hr light cycle.

15

More specifically, 12.5 mg of arachidonyl α -isopropylethanolamide and 1000 mg of 2-OH-propyl- β -CD were added to distilled water, and the solution was adjusted to pH 7.0 with sodium hydroxide/hydrochloric acid. Then, distilled water was added to adjust the total volume to 5.0 ml. The osmolality of the solution was adjusted to isotonic, 308 mOsm/kg, with sodium chloride.

20

As a control, a 0.9% (w/v) NaCl was also prepared.

25

Then, 25 μ l of either the drug-CD solution or the NaCl solution was administered unilaterally to the rabbits. The rabbits were kept in restraint boxes during the study.

30

IOP was measured using a BioRad (Cambridge, MA) Digilab Modular One Pneumatometer. Before each measurement, one or two drops of 0.06% (w/v) oxybuprocaine were applied to the cornea as an anaesthetic before tonometry to eliminate discomfort. For each determination, at least two readings were taken from each eye. The measurements were started 2 hr before drug-CD or 0.9% (w/v) NaCl solution

administration, and were continued for 5 hr after administration.

The IOPs of the pigmented rabbits at the time of eyedrop administration were between 21.4-29.5 mmHg (n = 6).

The results are shown in Figures 18A and 18B, and Table IV above. All of the values are expressed as mean \pm standard error of means ($X \pm S.E.$).

As shown in Figure 18A and Table IV above, unilateral ocular administration of arachidonyl α -isopropylethanolamide decreases the IOP in treated eyes in normotensive pigmented rabbits when compared to administration of a 0.9% (w/v) NaCl solution. In the treated eyes of normotensive pigmented rabbits, cyclodextrin vehiculated arachidonyl α -isopropylethanolamide showed a maximal IOP reduction of 3.8 mmHg, 2 hr after 0.25% (w/v) arachidonyl α -isopropylethanolamide treatment.

However, as shown in Figure 18B and Table IV above, unilateral ocular administration does affect also on IOP in the contralateral (untreated) eye in normotensive pigmented rabbits when compared to administration of the 0.9% (w/v) NaCl solution. In the contralateral eye of normotensive pigmented rabbits, the maximal IOP reduction was 3.7 mmHg, 2 hr after 0.25% (w/v) arachidonyl α -isopropylethanolamide treatment.

EXAMPLE 11

In this example, the effect of a 0.20% (w/v) arachidonyl α -phenylethanolamide solution on IOP of normotensive pigmented rabbits weighing between 2.6-3.6 kg (n = 6) was studied. The rabbits were housed separately in cages under standard laboratory conditions, i.e., 10 hr dark/14 hr light cycle.

More specifically, 10 mg of arachidonyl α -phenylethanolamide and 1000 mg of 2-OH-propyl- β -CD were added to distilled water, and the solution was adjusted to pH 7.0 with sodium hydroxide/hydrochloric acid. Then, distilled water was added to adjust the total volume to 5.0 ml. The osmolality of the solution was adjusted to isotonic, 319 mOsm/kg, with sodium chloride.

As a control, a 0.9% (w/v) NaCl was also prepared.

Then, 25 μ l of either the drug-CD solution or the NaCl solution was administered unilaterally to the rabbits. The rabbits were kept in restraint boxes during the study.

IOP was measured using a BioRad (Cambridge, MA) Digilab Modular One Pneumatometer. Before each measurement, one or two drops of 0.06% (w/v) oxybuprocaine were applied to the cornea as an anaesthetic before tonometry to eliminate discomfort. For each determination, at least two readings were taken from each eye. The measurements were started 2 hr before drug-CD or 0.9% (w/v) NaCl solution administration, and were continued for 5 hr after administration.

The IOPs of the pigmented rabbits at the time of eyedrop administration were between 19.2-29.6 mmHg (n = 6).

The results are shown in Figures 19A and 19B, and Table IV above. All of the values are expressed as mean \pm standard error of means (X \pm S.E.).

As shown in Figure 19A and Table IV above, unilateral ocular administration of arachidonyl α -phenylethanolamide decreases the IOP in treated eyes in normotensive pigmented rabbits when compared to administration of a 0.9% (w/v) NaCl solution. In the

treated eyes of normotensive pigmented rabbits, cyclodextrin vehiculated arachidonyl α -phenylethanolamide showed a maximal IOP reduction of 0.9 mmHg, 2 hr after 0.2% (w/v) arachidonyl α -phenylethanolamide treatment.

However, as shown in Figure 19B and Table IV above, unilateral ocular administration does affect also the IOP in the contralateral (untreated) eye in normotensive pigmented rabbits when compared to administration of the 0.9% (w/v) NaCl solution. In the contralateral eye of normotensive pigmented rabbits, the maximal IOP reduction was 0.9 mmHg, 2 hr after 0.2% (w/v) arachidonyl α -phenylethanolamide treatment.

Accordingly, based on the foregoing results, it is apparent that anandamides (or metabolites thereof) represented by Formula (I), such as ethanethiolamide, arachidonyl β -phenethylamide, arachidonyl aminoethylamide, arachidonyl N,N-dimethylaminoethylamide, arachidonyl N-acetylaminoethylamide, arachidonyl pyridinoethylamide, arachidonyl propionitrileamide, and arachidonyl morpholineamide appear to act to lower IOP without causing an appreciable initial hypertensive phase.

Also, based on the foregoing results, it is apparent that anandamides (or metabolites thereof) which act to lower IOP, but demonstrate an initial hypertensive phase, can be modified with a moiety at the carbon α to the amide nitrogen, to eliminate this effect, as represented by the anandamides of Formula (II). Examples of such a modification to eliminate this initial hypertensive phase include, but are not limited to, arachidonyl α -dimethylethanolamide, arachidonyl

α -isopropylethanolamide, and arachidonyl
 α -phenylethanolamide.

5 These drugs appear to act locally within the
treated eye, perhaps via a specific receptor or
prostaglandin-mediated mechanism, rather than via the
central nervous system. In cases where a
contralateral eye IOP lowering effect occurs, uptake
of the drug (or metabolites) diffused into the
10 bloodstream from the treated eye is the probable
mechanism of action (Salminen et al, Exp. Eye Res.,
38:203 (1984)). Although the mechanism of action by
which anandamides represented by Formula (I) and
Formula (II) produce their hypotensive effect in the
eye is not entirely understood, these results indicate
15 that they are promising drugs for treatment of
intraocular hypertension. The results also indicate
that cyclodextrin-vehiculated anandamides of
Formula (I) and Formula (II) are suitable for topical
ocular administration.


20 While the invention has been described in detail,
and with reference to specific embodiments thereof, it
will be apparent to one of ordinary skill in the art
that various changes and modifications can be made
therein without departing from the spirit and scope
25 thereof.

WHAT IS CLAIMED IS:

Claim 1. An ophthalmic composition for reducing intraocular pressure comprising an admixture of:

(A) a pharmaceutically effective amount of an anandamide represented by Formula (I) or Formula (II):

Formula (I):



5 wherein

Q is N;

R¹ and R² are each H, an alkyl of from 1 to 3 carbon atoms or (CH₂)_a-R³, wherein a is an integer of from 0 to 6;

10 R³ is:

(1) C≡N or SH;


(2) a carbocyclic ring having from 3 to 7 carbon atoms or a heterocyclic ring having from 3 to 7 atoms, at least one of which is a heteroatom selected from the group consisting of N, O and S;

15

(3) R⁴NR⁵, wherein R⁴ and R⁵ are each H or (CH₂)_n-CR⁶R⁷R⁸, wherein n is an integer of from 0 to 3, and R⁶, R⁷ and R⁸ are each H or (CH₂)_p-CH₃, wherein p is an integer of from 0 to 3; or

20

25



30

35

R^1 and R^2 may be combined together with Q to form a heterocyclic ring having 3 to 7 atoms, wherein the heterocyclic ring may have an additional heteroatom(s) selected from the group consisting of N, O and S, preferably morpholino;

x is an integer of from 0 to 18;


y is an integer of from 0 to 8; and

40

z is an integer of from 0 to 18;

wherein $x + y + z \leq 36$, or

Formula (II):



Q is N;

45

$\text{R}^{1'}$ and $\text{R}^{2'}$ are each H, an alkyl of from 1 to 3 carbon atoms or $(\text{R}^{4'}\text{CR}^{5'})-(\text{CH}_2)_a-\text{R}^{3'}$, wherein a' is an integer of from 0 to 5;

$\text{R}^{3'}$ is:

(1) OH, SH, $\text{C}\equiv\text{CH}$, $\text{C}\equiv\text{N}$, F, Cl, Br or I;

50

(2) a carbocyclic ring having from 3 to 7 carbon atoms, or a heterocyclic ring having from 3 to 7 atoms, at least one of

which is a heteroatom selected from the group consisting of N, O and S;

- (3) R^4NR^5 , wherein R^4 and R^5 are each H or $(CH_2)_n-CR^6R^7R^8$, wherein n is an integer of from 0 to 3, and R^6 , R^7 and R^8 are each H or $(CH_2)_p-CH_3$, wherein p is an integer of from 0 to 3;

- (4) $NH-\overset{\overset{O}{\parallel}}{C}-R^9$, wherein R^9 is H or $(CH_2)_q-CR^{10}R^{11}R^{12}$, wherein q is an integer of from 0 to 3, and R^{10} , R^{11} and R^{12} are each H or $(CH_2)_r-CH_3$, wherein r is an integer of from 0 to 3; or

- (5) $OCR^{13}R^{14}R^{15}$, wherein R^{13} , R^{14} , R^{15} are each H or $(CH_2)_s-CH_3$, wherein s is an integer of from 0 to 3;

$R^{4'}$ and $R^{5'}$ are each H, $(CH_2)_l-R^{3'}$, wherein $R^{3'}$ is a carbocyclic ring having from 3 to 7 carbon atoms, or a heterocyclic ring having from 3 to 7 atoms, at least one of which is a heteroatom selected from the group consisting of N, O and S, or $(CH_2)_l-CR^{6'}R^{7'}R^{8'}$, wherein l is an integer of from 0 to 3, and $R^{6'}$, $R^{7'}$, and $R^{8'}$ are each H or $(CH_2)_m-CH_3$, wherein m is an integer of from 0 to 3;

$R^{1'}$ and $R^{2'}$ may be combined together with Q to form a heterocyclic ring having 3 to 7 atoms, wherein the heterocyclic ring may have an additional heteroatom(s) selected from the group consisting of N, O and S;

$R^{4'}$ and $R^{5'}$ may be combined together to form a carbocyclic ring having from 3 to 7 carbon atoms, or may be combined with a heteroatom(s) selected from the

group consisting of N, O and S to form a heterocyclic ring having from 3 to 7 atoms;

R^4 or R^5 may be combined together with Q to form a heterocyclic ring having from 3 to 7 atoms, wherein the heterocyclic ring may have an additional heteroatom(s) selected from the group consisting of N, O and S;

x is an integer of from 0 to 18;

y is an integer of from 0 to 8; and

z is an integer of from 0 to 18;

wherein $x + y + z \leq 36$; and

(B) a cyclodextrin.

Claim 2. The ophthalmic composition according to Claim 1, wherein a is an integer of from 1 to 4, a' is an integer of 0 to 3.

Claim 3. The ophthalmic composition according to Claim 2, wherein a is an integer of from 2 to 3.

Claim 4. The ophthalmic composition according to Claim 1, wherein one of R^1 and R^2 is H or an alkyl having from 1 to 3 carbon atoms and the other of R^1 and R^2 is $(CH_2)_a-R^3$; and one of $R^{1'}$ and $R^{2'}$ is H or an alkyl having from 1 to 3 carbon atoms and the other of $R^{1'}$ and $R^{2'}$ is $(R^{4'}CR^{5'})-(CH_2)_a-R^{3'}$.

Claim 5. The ophthalmic composition according to Claim 1, wherein

Q is N;

R^3 is:

(1) $C \equiv N$;

(2) the carboxylic ring is phenyl, and the heterocyclic ring is pyridino or morpholino; or

(3) R^4NR^5 , wherein R^4 and R^5 are each H or $(CH_2)_n-CR^6R^7R^8$, wherein n is an integer of from 0 to 1, and R^6 , R^7 and R^8 are each H or $(CH_2)_p-CH_3$,

wherein p is an integer of from
0 to 1; or

15

- (4) $\text{NH}-\overset{\text{O}}{\parallel}{\text{C}}-\text{R}^9$, wherein R^9 is H or
 $(\text{CH}_2)_q-\text{CR}^{10}\text{R}^{11}\text{R}^{12}$, wherein q is an
integer of from 0 to 1, and R^{10} ,
20 R^{11} and R^{12} are each H or
 $(\text{CH}_2)_r-\text{CH}_3$, wherein r is an integer
of from 0 to 3;

$\text{R}^{3'}$ is:

25

- (1) SH, F, $\text{C}\equiv\text{CH}$ or $\text{C}\equiv\text{N}$;
(2) the carboxylic ring is phenyl,
and the heterocyclic ring is
pyridino or morpholino;
(3) R^4NR^5 , wherein R^4 and R^5 are each H
or $(\text{CH}_2)_n-\text{CR}^6\text{R}^7\text{R}^8$, wherein n is an
integer of from 0 to 1, and R^6 , R^7
30 and R^8 are each H or $(\text{CH}_2)_p-\text{CH}_3$,
wherein p is an integer of from
0 to 1;

35

- (4) $\text{NH}-\overset{\text{O}}{\parallel}{\text{C}}-\text{R}^9$, wherein R^9 is H or
 $(\text{CH}_2)_q-\text{CR}^{10}\text{R}^{11}\text{R}^{12}$, wherein q is an
integer of from 0 to 1, and R^{10} ,
40 R^{11} and R^{12} are each H or
 $(\text{CH}_2)_r-\text{CH}_3$, wherein r is an integer
of from 0 to 3; or

- (5) $\text{OCR}^{13}\text{R}^{14}\text{R}^{15}$, wherein R^{13} , R^{14} , R^{15} are
each H or $(\text{CH}_2)_s-\text{CH}_3$, wherein s is
an integer of from 0 to 1;

l is 0 to 1; only one of $\text{R}^{4'}$ and $\text{R}^{5'}$ is H;

45

R^1 and R^2 may be combined together with Q to form
a morpholino; and $\text{R}^{1'}$ and $\text{R}^{2'}$ may be combined together
with Q to form a morpholino; and

x is an integer of from 2 to 5;
y is an integer of from 2 to 4; and
z is an integer of from 2 to 5

50

wherein $x + y + z \leq 24$.

Claim 6. The ophthalmic composition according to Claim 5, wherein R^3 is $C \equiv N$, and $R^{3'}$ is $C \equiv CH$ or $C \equiv N$.

Claim 7. The ophthalmic composition according to Claim 6, wherein $R^{3'}$ is $C \equiv N$.

Claim 8. The ophthalmic composition according to Claim 1, wherein said anandamide is selected from the group consisting of arachidonyl ethanethiolamide, arachidonyl β -phenethylamide, arachidonyl aminoethylamide, arachidonyl N,N-dimethylaminoethylamide, arachidonyl N-acetylaminoethylamide, arachidonyl pyridinoethylamide, arachidonyl propionitrileamide, arachidonyl morpholineamide, arachidonyl α -isopropylethanolamide, arachidonyl α -methylethanolamide, arachidonyl α -dimethylethanolamide, arachidonyl α -phenylethanolamide, arachidonyl α -iso-butylethanolamide, and arachidonyl α -tert-butylethanolamide.

5

10

15

Claim 9. The ophthalmic composition according to Claim 1, wherein said cyclodextrin is 2-hydroxypropyl- β -cyclodextrin or heptakis-(2,6-O-methyl)- β -cyclodextrin.

20

Claim 10. The ophthalmic composition according to Claim 1, wherein said ophthalmic composition is an aqueous solution containing 0.01 to 2.0% (w/v) of said anandamide represented by Formula (I) or (II), and 0.5 to 40% (w/v) of a cyclodextrin.

25

Claim 11. The ophthalmic composition according to Claim 10, wherein said ophthalmic composition is an aqueous solution containing 0.1 to 0.5% (w/v) of said

30 anandamide represented by Formula (I) or (II), and
5.0 to 25% (w/v) of a cyclodextrin.

Claim 12. The ophthalmic composition according to
Claim 10, wherein the composition further comprises a
water-soluble polymeric compound as a viscosity
enhancing agent.

35 Claim 13. The ophthalmic composition according to
Claim 12, wherein said water-soluble polymeric
compound is selected from the group consisting of
hydroxypropylmethyl cellulose, hydroxyethyl cellulose,
hydroxypropyl cellulose, methyl cellulose, polyvinyl
40 alcohols, sodium polyacrylate, sodium carboxymethyl
cellulose, polyvinyl pyrrolidone, hyaluronic acid, and
polyacrylic acid.

Claim 14. The ophthalmic composition according to
Claim 12, wherein the viscosity enhancing agent is
45 present in an amount to give a viscosity in the range
of 1 to 1,000 cP.

Claim 15. The ophthalmic composition according to
Claim 14, wherein the viscosity enhancing agent is
present in an amount to give a viscosity in the range
50 of 5 to 50 cP.

Claim 16. The ophthalmic composition according to
Claim 10, wherein the composition further comprises a
buffering agent.

Claim 17. The ophthalmic composition according to
55 Claim 16, wherein said buffering agent is selected
from the group consisting of acetate, citrate,
phosphate, borate buffers, and a mixture thereof.

Claim 18. The ophthalmic composition according to
Claim 16, wherein the concentration of the buffering
60 agent is about 1.0 mM to 200 mM.


Claim 19. The ophthalmic composition according to
Claim 18, wherein the concentration of the buffering
agent is about 10 mM to 100 mM.

65

Claim 20. The ophthalmic composition according to Claim 16, wherein the solution has a pH in the range of 4.0 to 8.0.

70

Claim 21. A method for the treatment of intraocular hypertension, comprising topically administering to an eye of a subject in need of such treatment, a pharmaceutically effective amount of an anandamide represented by Formula (I):



wherein

Q is N;

75

R¹ and R² are each H, an alkyl of from 1 to 3 carbon atoms or (CH₂)_a-R³, wherein a is an integer of from 0 to 6;

R³ is:

80

- (1) C≡N or SH;
- (2) a carbocyclic ring having from 3 to 7 carbon atoms or a heterocyclic ring having from 3 to 7 atoms, at least one of which is a heteroatom selected from the group consisting of N, O and S;
- (3) R⁴NR⁵, wherein R⁴ and R⁵ are each H or (CH₂)_n-CR⁶R⁷R⁸, wherein n is an integer of from 0 to 3, and R⁶, R⁷ and R⁸ are each H or (CH₂)_p-CH₃, wherein p is an integer of from 0 to 3; or

85

90


95 (4) $\text{NH}-\overset{\text{O}}{\parallel}{\text{C}}-\text{R}^9$, wherein R^9 is H or
 $(\text{CH}_2)_q-\text{CR}^{10}\text{R}^{11}\text{R}^{12}$, wherein q is an
integer of from 0 to 3, and R^{10} ,
 R^{11} and R^{12} are each H or
 $(\text{CH}_2)_r-\text{CH}_3$, wherein r is an integer
of from 0 to 3;

100 R^1 and R^2 may be combined together with Q to form
a heterocyclic ring having 3 to 7 atoms, wherein the
heterocyclic ring may have an additional heteroatom(s)
selected from the group consisting of N, O and S,
preferably morpholino;

105 x is an integer of from 0 to 18;
y is an integer of from 0 to 8; and
z is an integer of from 0 to 18;

wherein $x + y + z \leq 36$, or

Formula (II):



110 Q is N;

$\text{R}^{1'}$ and $\text{R}^{2'}$ are each H, an alkyl of from 1 to 3
carbon atoms or $(\text{R}^{4'}\text{CR}^{5'})-(\text{CH}_2)_{a'}-\text{R}^{3'}$, wherein a' is an
integer of from 0 to 5;

$\text{R}^{3'}$ is:

- 115 (1) OH, SH, $\text{C}\equiv\text{CH}$, $\text{C}\equiv\text{N}$, F, Cl, Br or
I;
- (2) a carbocyclic ring having from
3 to 7 carbon atoms, or a
heterocyclic ring having from
120 3 to 7 atoms, at least one of

which is a heteroatom selected from the group consisting of N, O and S;

125 (3) R^4NR^5 , wherein R^4 and R^5 are each H or $(CH_2)_n-CR^6R^7R^8$, wherein n is an integer of from 0 to 3, and R^6 , R^7 and R^8 are each H or $(CH_2)_p-CH_3$, wherein p is an integer of from 0 to 3;

130 (4) $NH-\overset{\overset{O}{\parallel}}{C}-R^9$, wherein R^9 is H or $(CH_2)_q-CR^{10}R^{11}R^{12}$, wherein q is an integer of from 0 to 3, and R^{10} , R^{11} and R^{12} are each H or $(CH_2)_r-CH_3$, wherein r is an integer of from 0 to 3; or

135 (5) $OCR^{13}R^{14}R^{15}$, wherein R^{13} , R^{14} , R^{15} are each H or $(CH_2)_s-CH_3$, wherein s is an integer of from 0 to 3;

140 $R^{4'}$ and $R^{5'}$ are each H, $(CH_2)_\ell-R^{3'}$, wherein $R^{3'}$ is a carbocyclic ring having from 3 to 7 carbon atoms, or a heterocyclic ring having from 3 to 7 atoms, at least one of which is a heteroatom selected from the group consisting of N, O and S, or $(CH_2)_\ell-CR^{6'}R^{7'}R^{8'}$, wherein ℓ is an integer of from 0 to 3, and $R^{6'}$, $R^{7'}$, and $R^{8'}$ are each H or $(CH_2)_m-CH_3$, wherein m is an integer of from 0 to 3;

145 $R^{1'}$ and $R^{2'}$ may be combined together with Q to form a heterocyclic ring having 3 to 7 atoms, wherein the heterocyclic ring may have an additional heteroatom(s) selected from the group consisting of N, O and S;

150 $R^{4'}$ and $R^{5'}$ may be combined together to form a carbocyclic ring having from 3 to 7 carbon atoms, or may be combined with a heteroatom(s) selected from the

group consisting of N, O and S to form a heterocyclic ring having from 3 to 7 atoms;

R^4 or R^5 may be combined together with Q to form a heterocyclic ring having from 3 to 7 atoms, wherein the heterocyclic ring may have an additional heteroatom(s) selected from the group consisting of N, O and S;

x is an integer of from 0 to 18;

y is an integer of from 0 to 8; and

z is an integer of from 0 to 18;

wherein $x + y + z \leq 36$; and

(B) a cyclodextrin.

Claim 22. The method according to Claim 21, wherein a is an integer of from 1 to 4, a' is an integer of 0 to 3.

Claim 23. The method according to Claim 22, wherein a is an integer of from 2 to 3.

Claim 24. The method according to Claim 21, wherein one of R^1 and R^2 is H or an alkyl having from 1 to 3 carbon atoms and the other of R^1 and R^2 is $(CH_2)_a-R^3$; and one of $R^{1'}$ and $R^{2'}$ is H or an alkyl having from 1 to 3 carbon atoms and the other of $R^{1'}$ and $R^{2'}$ is $(R^{4'}CR^{5'})-(CH_2)_{a'}-R^{3'}$.

Claim 25. The method according to Claim 1, wherein

Q is N;

R^3 is:

(1) $C \equiv N$;

(2) the carboxylic ring is phenyl, and the heterocyclic ring is pyridino or morpholino; or

(3) R^4NR^5 , wherein R^4 and R^5 are each H or $(CH_2)_n-CR^6R^7R^8$, wherein n is an integer of from 0 to 1, and R^6 , R^7 and R^8 are each H or $(CH_2)_p-CH_3$,

wherein p is an integer of from 0 to 1; or

15

- (4) $\text{NH}-\overset{\text{O}}{\parallel}{\text{C}}-\text{R}^9$, wherein R^9 is H or $(\text{CH}_2)_q-\text{CR}^{10}\text{R}^{11}\text{R}^{12}$, wherein q is an integer of from 0 to 1, and R^{10} , R^{11} and R^{12} are each H or $(\text{CH}_2)_r-\text{CH}_3$, wherein r is an integer of from 0 to 3;

20

$\text{R}^{3'}$ is:

- (1) SH, F, $\text{C}\equiv\text{CH}$ or $\text{C}\equiv\text{N}$;
 (2) the carboxylic ring is phenyl, and the heterocyclic ring is pyridino or morpholino;
 (3) R^4NR^5 , wherein R^4 and R^5 are each H or $(\text{CH}_2)_n-\text{CR}^6\text{R}^7\text{R}^8$, wherein n is an integer of from 0 to 1, and R^6 , R^7 and R^8 are each H or $(\text{CH}_2)_p-\text{CH}_3$, wherein p is an integer of from 0 to 1;

25

30

35

- (4) $\text{NH}-\overset{\text{O}}{\parallel}{\text{C}}-\text{R}^9$, wherein R^9 is H or $(\text{CH}_2)_q-\text{CR}^{10}\text{R}^{11}\text{R}^{12}$, wherein q is an integer of from 0 to 1, and R^{10} , R^{11} and R^{12} are each H or $(\text{CH}_2)_r-\text{CH}_3$, wherein r is an integer of from 0 to 3; or
 (5) $\text{OCR}^{13}\text{R}^{14}\text{R}^{15}$, wherein R^{13} , R^{14} , R^{15} are each H or $(\text{CH}_2)_s-\text{CH}_3$, wherein s is an integer of from 0 to 1;

40

ℓ is 0 to 1; only one of $\text{R}^{4'}$ and $\text{R}^{5'}$ is H;

45

R^1 and R^2 may be combined together with Q to form a morpholino; and $\text{R}^{1'}$ and $\text{R}^{2'}$ may be combined together with Q to form a morpholino; and

x is an integer of from 2 to 5;
y is an integer of from 2 to 4; and
z is an integer of from 2 to 5

50

wherein $x + y + z \leq 24$.

Claim 26. The method according to Claim 25, wherein R^3 is $C \equiv N$, and $R^{3'}$ is $C \equiv CH$ or $C \equiv N$.

Claim 27. The method according to Claim 21, wherein $R^{3'}$ is $C \equiv N$.

Claim 28. The method according to Claim 21, wherein said anandamide is selected from the group consisting of arachidonyl ethanethiolamide, arachidonyl β -phenethylamide, arachidonyl aminoethylamide, arachidonyl N,N-dimethylaminoethylamide, arachidonyl N-acetylaminoethylamide, arachidonyl pyridinoethylamide, arachidonyl propionitrileamide, arachidonyl morpholineamide, arachidonyl α -isopropylethanolamide, arachidonyl α -methylethanolamide, arachidonyl α -dimethylethanolamide, arachidonyl α -phenylethanolamide, arachidonyl α -iso-butylethanolamide, and arachidonyl α -tert-butylethanolamide.

5

10

15

Claim 29. The method according to Claim 21, wherein said anandamide is co-administered with a cyclodextrin.

Claim 30. The method according to Claim 29, said cyclodextrin is 2-hydroxypropyl- β -cyclodextrin or heptakis-(2,6-O-methyl)- β -cyclodextrin.

20

Claim 31. The method according to Claim 29, wherein said ophthalmic composition is an aqueous solution containing 0.01 to 2.0% (w/v) of said anandamide represented by Formula (I) or (II), and 0.5 to 40% (w/v) of a cyclodextrin.

25

30 Claim 32. The method according to Claim 31,
wherein said ophthalmic composition is an aqueous
solution containing 0.1 to 0.5% (w/v) of said
anandamide represented by Formula (I) or (II), and
5.0 to 25% (w/v) of a cyclodextrin.

35 Claim 33. The method according to Claim 31,
wherein the composition further comprises a
water-soluble polymeric compound as a viscosity
enhancing agent.

40 Claim 34. The method according to Claim 33,
wherein said water-soluble polymeric compound is
selected from the group consisting of
hydroxypropylmethyl cellulose, hydroxyethyl cellulose,
hydroxypropyl cellulose, methyl cellulose, polyvinyl
alcohols, sodium polyacrylate, sodium carboxymethyl
cellulose, polyvinyl pyrrolidone, hyaluronic acid, and
polyacrylic acid.

45 Claim 35. The method according to Claim 33,
wherein the viscosity enhancing agent is present in an
amount to give a viscosity in the range of 1 to
1,000 cP.

50 Claim 36. The method according to Claim 35,
wherein the viscosity enhancing agent is present in an
amount to give a viscosity in the range of 5 to 50 cP.

Claim 37. The method according to Claim 31,
wherein the composition further comprises a buffering
agent.

55 Claim 38. The method according to Claim 37,
wherein said buffering agent is selected from the
group consisting of acetate, citrate, phosphate,
borate buffers, and a mixture thereof.

60 Claim 39. The method according to Claim 37,
wherein the concentration of the buffering agent is
about 1.0 mM to 200 mM.

Claim 40. The method according to Claim 39, wherein the concentration of the buffering agent is about 10 mM to 100 mM.

65

Claim 41. The method according to Claim 37, wherein the solution has a pH in the range of 4.0 to 8.0.

FIGURE 1A




FIGURE 1B




FIGURE 2A




FIGURE 2B




FIGURE 3A




FIGURE 3B




FIGURE 4A




FIGURE 4B




FIGURE 5A




FIGURE 5B




FIGURE 6A




FIGURE 6B




FIGURE 7A




FIGURE 7B




FIGURE 8A




FIGURE 8B




FIGURE 9A




FIGURE 9B




FIGURE 10A




FIGURE 10B




FIGURE 11A




FIGURE 11B




FIGURE 12A




FIGURE 12B




FIGURE 13A




FIGURE 13B




FIGURE 14A




FIGURE 14B




FIGURE 15A




FIGURE 15B




FIGURE 16A




FIGURE 16B




FIGURE 17A




FIGURE 17B




FIGURE 18A




FIGURE 18B




FIGURE 19A





FIGURE 19B



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/08226

<p>A. CLASSIFICATION OF SUBJECT MATTER IPC(6) :A01N 37/18, 37/34; A61K 31/16, 31/275 US CL :514/528, 626, 627, 628, 629, 912, 913 According to International Patent Classification (IPC) or to both national classification and IPC</p>																																	
<p>B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/528, 626, 627, 628, 629, 912, 913</p> <p>Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched</p> <p>Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Extra Sheet.</p>																																	
<p>C. DOCUMENTS CONSIDERED TO BE RELEVANT</p> <table border="1"> <thead> <tr> <th>Category*</th> <th>Citation of document, with indication, where appropriate, of the relevant passages</th> <th>Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td>Y</td> <td>US, A, 4,474,811 (MASUDA ET AL) 02 October 1984, columns 4 and 5.</td> <td>1-41</td> </tr> <tr> <td>Y</td> <td>US, A, 4,983,586 (BODOR) 08 January 1991, columns 14 and 15.</td> <td>1-41</td> </tr> <tr> <td>Y, P</td> <td>US, A, 5,418,225 (JAVITT ET AL) 23 May 1995, columns 3-9.</td> <td>1-41</td> </tr> <tr> <td>Y</td> <td>WO 94/12466, (DEVANE ET AL) 09 June 1994, pages 8, 9, 19, 4/9 and 9/9.</td> <td>1-41</td> </tr> </tbody> </table> <p><input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.</p> <table border="1"> <tr> <td>* Special categories of cited documents:</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"E" earlier document published on or after the international filing date</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"&" document member of the same patent family</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td></td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table> <table border="1"> <tr> <td>Date of the actual completion of the international search 11 OCTOBER 1995</td> <td>Date of mailing of the international search report 06 NOV 1995</td> </tr> <tr> <td>Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230</td> <td>Authorized officer <i>Rosalyn A. Williams</i> ROSALYND A. WILLIAMS Telephone No. (703) 308-1235</td> </tr> </table>			Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	Y	US, A, 4,474,811 (MASUDA ET AL) 02 October 1984, columns 4 and 5.	1-41	Y	US, A, 4,983,586 (BODOR) 08 January 1991, columns 14 and 15.	1-41	Y, P	US, A, 5,418,225 (JAVITT ET AL) 23 May 1995, columns 3-9.	1-41	Y	WO 94/12466, (DEVANE ET AL) 09 June 1994, pages 8, 9, 19, 4/9 and 9/9.	1-41	* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family	"O" document referring to an oral disclosure, use, exhibition or other means		"P" document published prior to the international filing date but later than the priority date claimed		Date of the actual completion of the international search 11 OCTOBER 1995	Date of mailing of the international search report 06 NOV 1995	Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer <i>Rosalyn A. Williams</i> ROSALYND A. WILLIAMS Telephone No. (703) 308-1235
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																															
Y	US, A, 4,474,811 (MASUDA ET AL) 02 October 1984, columns 4 and 5.	1-41																															
Y	US, A, 4,983,586 (BODOR) 08 January 1991, columns 14 and 15.	1-41																															
Y, P	US, A, 5,418,225 (JAVITT ET AL) 23 May 1995, columns 3-9.	1-41																															
Y	WO 94/12466, (DEVANE ET AL) 09 June 1994, pages 8, 9, 19, 4/9 and 9/9.	1-41																															
* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																																
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																																
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																																
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family																																
"O" document referring to an oral disclosure, use, exhibition or other means																																	
"P" document published prior to the international filing date but later than the priority date claimed																																	
Date of the actual completion of the international search 11 OCTOBER 1995	Date of mailing of the international search report 06 NOV 1995																																
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer <i>Rosalyn A. Williams</i> ROSALYND A. WILLIAMS Telephone No. (703) 308-1235																																

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/08226

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, STN CAS

search terms: anandamide#, arachidony!?, buffering agent, acetate, citrate, phosphate, viscosity enhanc###, ?cellulose, polyvinyl alcohol, intraocular pressure, intraocular hypertnsion, glaucoma